

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

W protein - protein search, using sw model

run on: March 15, 2004, 07:25:43 ; Search time 60 Seconds
(without alignments)
1125.481 Million cell updates/sec

Title: US-09-620-955B-6

Perfect score: 1250
Sequence: 1 QVQLQESGGGLVQPGGSLRL.....CSFANSGLPLGGGRKTVTL 239

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1586107 seqs, 282547505 residues

Total number of hits satisfying chosen parameters: 1586107

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database: A-Geneseq_29Jan04.*

- 1: Geneseqp1980s.*
- 2: Geneseqp1990s.*
- 3: Geneseqp2000s.*
- 4: Geneseqp2001s.*
- 5: Geneseqp2002s.*
- 6: Geneseqp2003as.*
- 7: Geneseqp2003bs.*
- 8: Geneseqp2004s.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	DB	ID	Description
1	1250	100.0	239	4	AAB69603	AAB69603 Huntingt1
2	1110	88.8	254	5	ABP44972	ABP44972 Human Bly
3	1106	88.5	256	5	ABP44828	ABP44828 Human Bly
4	1097	87.8	252	5	ABP45616	ABP45616 Human Bly
5	1096	87.7	254	5	ABP44970	ABP44970 Human Bly
6	1095.5	87.6	241	5	ABP46044	ABP46044 Human Bly
7	1093	87.4	252	5	ABP44945	ABP44945 Human Bly
8	1089.5	87.2	251	5	ABP44944	ABP44944 Human Bly
9	1089.5	87.2	251	5	ABP45306	ABP45306 Human Bly
10	1088.5	87.1	251	5	ABP45103	ABP45103 Human Bly
11	1084.5	86.8	253	5	ABP44992	ABP44992 Human Bly
12	1082.5	86.6	251	5	ABP45321	ABP45321 Human Bly
13	1079	86.3	254	5	ABP45690	ABP45690 Human Bly
14	1079	86.3	254	5	ABP45748	ABP45748 Human Bly
15	1078	86.2	256	5	ABP45381	ABP45381 Human Bly
16	1077.5	86.2	253	5	ABP44978	ABP44978 Human Bly
17	1077	86.2	254	5	ABP44870	ABP44870 Human Bly
18	1073.5	85.9	253	5	ABP44996	ABP44996 Human Bly
19	1072	85.8	244	5	ABP45899	ABP45899 Human Bly
20	1067	85.4	254	5	ABP44966	ABP44966 Human Bly
21	1065	85.2	240	5	ABP46036	ABP46036 Human Bly
22	1065	85.2	254	5	ABP45417	ABP45417 Human Bly
23	1064.5	85.2	253	5	ABP45438	ABP45438 Human Bly
24	1063	85.0	254	5	ABP45064	ABP45064 Human Bly
25	1062	85.0	254	5	ABP45724	ABP45724 Human Bly

ABP45594 Human Bly
ABP45326 Human Bly
ABP45303 Human Bly
ABP45662 Human Bly
ABP45887 Human Bly
ABP45420 Human Bly
ABP45679 Human Bly
ABP45919 Human Bly
ABP45313 Human Bly
ABP44872 Human Bly
ABP46066 Human Bly
ABP44984 Human Bly
ABP44904 Human Bly
ABP45623 Human Bly
ABP45771 Human Bly
ABP44912 Human Bly
Aao31142 Human CM0
ABP45642 Human Bly
ABP44914 Human Bly
ABP45808 Human Bly

ALIGNMENTS

RESULT 1
AAB69603
ID AAB69603 standard; protein; 239 AA.

XX AAB69603;
XX AC
XX DT 30-APR-2001 (first entry)
XX DE Huntingtin intrabody alpha-Nt-HD-C4 sFV.

XX Neurological disorder; Huntington's disease; Alzheimer's disease;
KW Parkinson's disease; prion disease; frontotemporal dementia;
KW amyotrophic lateral sclerosis; spinal and bulbar muscular atrophy;
KW dentatorubral-pallidoluysian atrophy; spinocerebellar ataxia type 1; SCA2;
KW SCA3; SCA4; SCA5; SCA6; SCA7; protein accumulation; intrabody.

XX Unidentified.

XX WO200106989-A2.

XX PD 01-FEB-2001.

XX PF 24-JUL-2000; 2000WO-US020131.

XX PR 27-JUL-1999; 99US-0146047P.

XX PR 21-JUL-2000; 2000US-00620955.

XX PA (HUST/) HUSTON J S.

XX PA (MESS/) MESSER A.

XX PA (LECE/) LECERF J.

XX XX Huston JS, Messer A, Lecerf J;

XX WPI; 2001-182700/18.

XX N-PSDB; AAF58707.

XX Inhibiting intracellular polypeptide accumulation, useful for treating
neurological disorders, e.g. Alzheimer's disease, comprises contacting
the polypeptide with a specific intrabody.

XX Claim 22; Page 95; 109pp; English.

XX The present invention describes a method for inhibiting the formation of
aggregates of certain proteins, involving contacting the protein with a
binding molecule known as an intrabody. Proteins to be bound include
those associated with neurological disorders, and so the method can be
used in the prevention of diseases such as Alzheimer's, Parkinson's and
Huntington's diseases, prion diseases, frontotemporal dementia,

CC amyotrophic lateral sclerosis, spinal and bulbar muscular atrophy,
 CC dentatorubral-pallidoluysian atrophy, spinocerebellar ataxia type 1
 CC (SCA1), SCA2, SCA3, SCA4, SCA5, SCA6 and SCA7
 XX Sequence 239 AA;
 SQ Query Match 100.0%; Score 1250; DB 4; Length 239;
 Best Local Similarity 100.0%; Pred. No. 6.9e-81;
 Matches 239; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSYSSMSVRQAPGKLEWAVISYDGSNKYY 60
 Db 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSYSSMSVRQAPGKLEWAVISYDGSNKYY 60
 QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCARDYFDLWGRGTLVTVSSGGGGS 120
 Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCARDYFDLWGRGTLVTVSSGGGGS 120
 QY 121 GGGGGGGGSSALTPQASVSGSPQSSITISCTGTSSDIDGAYNVSVYQYQPGKAPKLLI 180
 Db 121 GGGGGGGGSSALTPQASVSGSPQSSITISCTGTSSDIDGAYNVSVYQYQPGKAPKLLI 180
 QY 181 YDVSNRPGISNRPFGSKSGDTASLTISGLQAEADYCYSSFNSSGPLEGGGKTVTL 239
 Db 181 YDVSNRPGISNRPFGSKSGDTASLTISGLQAEADYCYSSFNSSGPLEGGGKTVTL 239
 RESULT 2
 ABP44972
 ID ABP44972 standard; protein; 254 AA.
 XX AC ABP44972;
 XX DT 19-AUG-2002 (first entry)
 XX DE Human Blys binding scFv SEQ ID 983.
 XX KW Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
 KW tumour necrosis factor; B cell proliferation; B cell differentiation;
 KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
 KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
 KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
 KW common variable immunodeficiency; acquired immunodeficiency syndrome.
 XX OS Homo sapiens.
 XX WO200202641-A1.
 XX PD 10-JAN-2002.
 XX PF 15-JUN-2001; 2001WO-US019110.
 XX PR 16-JUN-2000; 2000US-0212210P.
 XX PR 17-OCT-2000; 2000US-0240816P.
 XX PR 16-MAR-2001; 2001US-0276248P.
 XX PR 21-MAR-2001; 2001US-0277379P.
 XX PR 25-MAY-2001; 2001US-0293499P.
 XX PA (HUMA-) HUMAN GENOME SCI INC.
 XX PA (CAME-) CAMBRIDGE ANTIBODY TECHNOLOGY.
 XX PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
 XX WPI; 2002-114799/15.
 XX PT Antibodies against B Lymphocyte Stimulating polypeptides, useful for the
 PT diagnosis and treatment of cancers and immune disorders.
 XX PS Claim 1; Page 1574-1575; 3148pp; English.
 XX CC This invention describes novel antibodies that immunospecifically bind to
 CC B Lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
 CC tumour necrosis factor (TNF) super family and induces B cell

CC proliferation and differentiation. The antibodies of the invention have
 CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
 CC antirheumatic and antiAIDS activity and can be used in vaccines to
 CC inhibit the expression and activity of Blys. The antibodies bind to Blys
 CC and so may be used to detect and quantitate the presence of Blys in
 CC biological samples and may be used in this way to diagnose disease
 CC associated with aberrant expression of Blys. They may also be
 CC administered to treat diseases associated with aberrant Blys expression
 CC and activity such as cancer, immune, and autoimmune disorders and
 CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
 CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
 CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
 CC the antibodies and fragments of the antibodies described in the method of
 CC the invention
 XX Sequence 254 AA;
 SQ Query Match 88.8%; Score 1110; DB 5; Length 254;
 Best Local Similarity 84.2%; Pred. No. 6.1e-71;
 Matches 213; Conservative 14; Mismatches 12; Indels 14; Gaps 2;
 QY 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSYSSMSVRQAPGKLEWAVISYDGSNKYY 60
 Db 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSYSSMSVRQAPGKLEWAVISYDGSNKYY 60
 QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCARDYFDLWGRGTLVTVSSGGGGS 120
 Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCARDYFDLWGRGTLVTVSSGGGGS 120
 QY 108 GTLVTVSSGGGSGGSGGSSALTPQASVSGSPQSSITISCTGTSSDIDGAYNVSV 167
 Db 121 GTLVTVSSGGGSGGSGGSSALTPQASVSGSPQSSITISCTGTSSDIDGAYNVSV 180
 QY 168 YQYQPGKAPKLLIYDVSNRPGISNRPFGSKSGDTASLTISGLQAEADYCYSSFNSS 226
 Db 181 YQYQPGKAPKLLIYDVSNRPGISNRPFGSKSGDTASLTISGLQAEADYCYSSFNSS 240
 QY 227 GPLFGGSGTKTVTL 239
 Db 241 TRVFGSGTKTVTL 253
 RESULT 3
 ABP44828
 ID ABP44828 standard; protein; 256 AA.
 XX AC ABP44828;
 XX DT 19-AUG-2002 (first entry)
 XX DE Human Blys binding scFv SEQ ID 839.
 XX KW Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
 KW tumour necrosis factor; B cell proliferation; B cell differentiation;
 KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
 KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
 KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
 KW common variable immunodeficiency; acquired immunodeficiency syndrome.
 XX OS Homo sapiens.
 XX WO200202641-A1.
 XX PD 10-JAN-2002.
 XX PF 15-JUN-2001; 2001WO-US019110.
 XX PR 16-JUN-2000; 2000US-0212210P.
 XX PR 17-OCT-2000; 2000US-0240816P.
 XX PR 16-MAR-2001; 2001US-0276248P.
 XX PR 21-MAR-2001; 2001US-0277379P.
 XX PR 25-MAY-2001; 2001US-0293499P.

2A (HUMA-) HUMAN GENOME SCI INC.
2A (CMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
2A Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
2A WPI; 2002-114799/15.
2A Antibodies against B Lymphocyte Stimulating polypeptides, useful for the
2A diagnosis and treatment of cancers and immune disorders.
2A Claim 1; Page 1402-1403; 3148pp; English.
2A This invention describes novel antibodies that immunospecifically bind to
2A B Lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
2A tumour necrosis factor (TNF) super family and induces B cell
2A proliferation and differentiation. The antibodies of the invention have
2A cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
2A antirheumatic and antiAIDS activity and can be used in vaccines to
2A inhibit the expression and activity of Blys. The antibodies bind to Blys
2A and so may be used to detect and quantitate the presence of Blys in
2A biological samples and may be used in this way to diagnose disease
2A associated with aberrant expression of Blys. They may also be
2A administered to treat diseases associated with aberrant Blys expression
2A and activity such as cancer, immune, and autoimmune disorders and
2A diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
2A immunodeficiency (e.g. common variable immunodeficiency (CVID) and
2A acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
2A the antibodies and fragments of the antibodies described in the method of
2A the invention
2A Sequence 256 AA;
2A Query Match 88.5%; Score 1106; DB 5; Length 256;
2A Best Local Similarity 83.9%; Pred. No. 1.2e-70;
2A Matches 213; Conservative 12; Mismatches 13; Indels 16; Gaps 2;
2A QY 2 VOLQESGGGLVQPGGSLRLSCAASGFTSSYSMSWVRQAPKGLEWAVISYDGSNKYYA 61
2A DB 2 VOLQESGGGVVQPGGSLRLSCAASGFTSSYGMHWVRQAPKGLEWAVISYDGSNKYYA 61
2A QY 62 DSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCARDR-----YFDLWG 106
2A DB 62 DSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCARDREAYVDILTYLYYYNDWG 121
2A QY 107 RGLTVVSSGGGGGGGGGGGGGQSALTPASVSGSGSITISCTGSSDYGAYNYS 166
2A DB 122 RGLTVVSSGGGGGGGGGGGGGQSALTPASVSGSGSITISCTGSSDYGAYNYS 181
2A QY 167 WYQHPGKAPKLLIYDVNSRPSGTSNRFSGSKSGDTASLTISGLQAEADYVCSF-AN 225
2A DB 182 WYQHPGKAPKLLIYDVNSRPSGTSNRFSGSKSGDTASLTISGLQAEADYVCSF-AN 241
2A QY 226 SGPLFGGKTKTVL 239
2A DB 242 STRVFGGKTKTVL 255
2A RESULT 4
2A ABP45616
2A ID ABP45616 standard; protein; 252 AA.
2A AC ABP45616;
2A XX
2A DT
2A DE
2A XX
2A XX
2A XX
2A Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
2A tumour necrosis factor; B cell proliferation; B cell differentiation;
2A immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
2A antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
2A systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
2A common variable immunodeficiency; acquired immunodeficiency syndrome.

```

C the invention
X Q Sequence 241 AA;
  Query Match 87.6%; Score 1095.5; DB 5; Length 241;
  Best Local Similarity 86.2%; Pred. No. 6.2e-70;
  Matches 207; Conservative 16; Mismatches 16; Indels 1; Gaps 1;

Y 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSYSSWVRQAPGKLEWVAIVSYDGNKYY 60
b 1 QVQLVQSGGDEVQPGSRRLSCAASGFTFSYSSWVRQAPGKLEWVAIVSYDGNKYY 60
  61 ADSVKGRTTISRDNSKNTLYLQMSLRAEDTAVYICARDRVFDLWGRGTTLVTVSSGGGGS 120
  61 ADSVKGRTTISRDNSKNTLYLQMSLRAEDTAVYICARDLDFYWGQGITLVTVSSGGGGS 120
  121 GGGGSGGGGSGSALTQPSASVSGSPQGSITISCTGTSSDIGAYNTVSYQYQPKAPKLLI 180
  121 GGGGSGGGGSGSALTQPPFSASGSPQGSITISCTGTSSDVGGYNYVSYQYQHPKAPKEMI 180
  181 YDVSNRPGISNRFSGSKSGDPTASLTISGLQAEADYICSSPAN-SGPIFGGQTKVTVL 239
  181 YDVSKRPGSVNRFSGSKSGNTASLTISGVQAEADYICSSYTSASTVIFGGGTKLTVL 240

RESULT 7
ID ABP44945 standard; protein; 252 AA.
CX AC ABP44945;
CX AC ABP44945;
DT 19-AUG-2002 (first entry)
CX DE Human BlyS binding scFv SEQ ID 956.
  BlyS; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
  tumour necrosis factor; B cell proliferation; B cell differentiation;
  immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
  anti-AIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
  systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
  common variable immunodeficiency; acquired immunodeficiency syndrome.
  Homo sapiens.
  WO200202641-A1.
  10-JAN-2002.
  15-JUN-2001; 2001WO-US019110.
  16-JUN-2000; 2000US-0212210P.
  17-OCT-2000; 2000US-0240816P.
  16-MAR-2001; 2001US-0276249P.
  21-MAR-2001; 2001US-0277379P.
  25-MAY-2001; 2001US-0293499P.
  (HUMA-) HUMAN GENOME SCI INC.
  (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
  Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
  WPI; 2002-114799/15.
  Antibodies against B Lymphocyte Stimulating polypeptides, useful for the
  diagnosis and treatment of cancers and immune disorders.
  Claim 1; Page 1542-1543; 3148pp; English.
  This invention describes novel antibodies that immunospecifically bind to
  B lymphocyte stimulator (BlyS) polypeptides. BlyS is a member of the
  tumour necrosis factor (TNF) super family and induces B cell
  proliferation and differentiation. The antibodies of the invention have
  cytostatic, immunosuppressive, immunostimulant, immunomodulatory,

```

```

CC antirheumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of BlyS. The antibodies bind to BlyS
CC and so may be used to detect and quantitate the presence of BlyS in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of BlyS. They may also be
CC administered to treat diseases associated with aberrant BlyS expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method of
CC the invention
XX SQ Sequence 252 AA;
  Query Match 87.4%; Score 1093; DB 5; Length 252;
  Best Local Similarity 84.1%; Pred. No. 9.8e-70;
  Matches 211; Conservative 12; Mismatches 16; Indels 12; Gaps 2;

QY 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSYSSWVRQAPGKLEWVAIVSYDGNKYY 60
DB 1 QVQLVESGGGVQPGGSLRLSCAASGFTFSYGMWVRQAPGKLEWVAIVSYDGSDDKY 60
  61 ADSVKGRTTISRDNSKNTLYLQMSLRAEDTAVYICARDP-----YFDLWGRGT 109
  61 EDSVKGRTTISRDNSKNTLYLQMSLRAEDTAVYICARDSGGDLITGYNYPFYDYGQGT 120
  110 LVTVSSGGGSGGGGSGSALTQPSASVSGSPQGSITISCTGTSSDIGAYNTVSYQY 169
  121 TTVTSSGGGSGGGGSGGGSQSVLTQPSASVSGSPQGSITISCTGTSSDVGGYNYVSYQ 180
  170 QYQKAPKLLIYDVSNRPGISNRFSGSKSGDPTASLTISGLQAEADYICSSP-ANSGP 228
  181 QHPGKAPKLMYEGSRPSPGVNRFSGSKSGNTASLTISGPQAEADYICSSYTRSTR 240
  229 LFGGGTKVTVL 239
  241 VFGGTKLTVL 251

RESULT 8
ID ABP44944 standard; protein; 251 AA.
CX AC ABP44944;
CX AC ABP44944;
DT 19-AUG-2002 (first entry)
CX DE Human BlyS binding scFv SEQ ID 955.
  BlyS; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
  tumour necrosis factor; B cell proliferation; B cell differentiation;
  immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
  anti-AIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
  systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
  common variable immunodeficiency; acquired immunodeficiency syndrome.
  Homo sapiens.
  WO200202641-A1.
  10-JAN-2002.
  15-JUN-2001; 2001WO-US019110.
  16-JUN-2000; 2000US-0212210P.
  17-OCT-2000; 2000US-0240816P.
  16-MAR-2001; 2001US-0276249P.
  21-MAR-2001; 2001US-0277379P.
  25-MAY-2001; 2001US-0293499P.
  (HUMA-) HUMAN GENOME SCI INC.
  (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.

```

```

XX  Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX  WPI; 2002-114799/15.
XX  Antibodies against B Lymphocyte Stimulating polypeptides, useful for the
XX  diagnosis and treatment of cancers and immune disorders.
XX  Claim 1; Page 1541-1542; 3148pp; English.
XX  This invention describes novel antibodies that immunospecifically bind to
XX  B Lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
XX  tumour necrosis factor (TNF) super family and induces B cell
XX  proliferation and differentiation. The antibodies of the invention have
XX  cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX  antirheumatic and antiAIDS activity and can be used in vaccines to
XX  inhibit the expression and activity of Blys. The antibodies bind to Blys
XX  and so may be used to detect and quantitate the presence of Blys in
XX  biological samples and may be used in this way to diagnose disease
XX  associated with aberrant expression of Blys. They may also be
XX  administered to treat diseases associated with aberrant Blys expression
XX  and activity such as cancer, immune, and autoimmune disorders and
XX  diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
XX  immunodeficiency (e.g. common variable immunodeficiency (CVID) and
XX  acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
XX  the antibodies and fragments of the antibodies described in the method of
XX  the invention.
XX  Sequence 251 AA;
XX  Query Match      87.2%; Score 1089.5; DB 5; Length 251;
XX  Best Local Similarity 83.6%; Pred. No. 1.7e-69;
XX  Matches 209; Conservative 14; Mismatches 16; Indels 11; Gaps 2;
XX  QY      1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSYSSMSVWRQAPGKLEWVAIVSYDGSNKYY 60
XX  Db      1 EQVLVESGGGVQPGERSLRSLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
XX  QY      61 ADSVKGRFTISRDNKNTLYLQMSLRADTAIVYCARDR-----YFDLWGRGTL 110
XX  Db      61 ADSVKGRFTVSRDNKNTLYLQMSLRADTAIVYCARDR-----YFDLWGRGTL 110
XX  QY      111 VTSSGGGGGGGGGGGGGSGGSGSALTQPASVSGSPQSGTITISGLQAEDEADYYCSSF-ANSGPL 229
XX  Db      121 VTSSGGGGGGGGGGGGGSGGSGSALTQPASVSGSPQSGTITISGLQAEDEADYYCSSF-ANSGPL 229
XX  QY      171 YPGKAPKLLIYDVSNRPGISNRFSGSKSGTASLTISGLQAEDEADYYCSSF-ANSGPL 229
XX  Db      181 HPGKAPKLLIYEGSKRPGVSNRFGSKSGTASLTISGLQAEDEADYYCSSF-ANSGPL 229
XX  QY      230 FGGGTRKTVTL 239
XX  Db      241 FGGGTRKTVL 250
XX  RESULT 9
XX  ABP45306
XX  ID ABP45306 standard; protein; 251 AA.
XX  AC ABP45306;
XX  KW Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
XX  PT tumour necrosis factor; B cell proliferation; B cell differentiation;
XX  DE immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
XX  DE artAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
XX  DE systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX  DE common variable immunodeficiency; acquired immunodeficiency syndrome.
XX  OS Homo sapiens.

```

```

XX  WO200202641-A1.
XX  10-JAN-2002.
XX  15-JUN-2001; 2001WO-US019110.
XX  16-JUN-2000; 2000US-0212210P.
XX  17-OCT-2000; 2000US-0240816P.
XX  16-MAR-2001; 2001US-0276248P.
XX  21-MAR-2001; 2001US-0277379P.
XX  25-MAY-2001; 2001US-0293499P.
XX  (HUMA-) HUMAN GENOME SCI INC.
XX  (CAMP-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX  Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX  WPI; 2002-114799/15.
XX  Antibodies against B Lymphocyte Stimulating polypeptides, useful for the
XX  diagnosis and treatment of cancers and immune disorders.
XX  Claim 1; Page 1974-1975; 3148pp; English.
XX  This invention describes novel antibodies that immunospecifically bind to
XX  B Lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
XX  tumour necrosis factor (TNF) super family and induces B cell
XX  proliferation and differentiation. The antibodies of the invention have
XX  cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX  antirheumatic and antiAIDS activity and can be used in vaccines to
XX  inhibit the expression and activity of Blys. The antibodies bind to Blys
XX  and so may be used to detect and quantitate the presence of Blys in
XX  biological samples and may be used in this way to diagnose disease
XX  associated with aberrant expression of Blys. They may also be
XX  administered to treat diseases associated with aberrant Blys expression
XX  and activity such as cancer, immune, and autoimmune disorders and
XX  diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
XX  immunodeficiency (e.g. common variable immunodeficiency (CVID) and
XX  acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
XX  the antibodies and fragments of the antibodies described in the method of
XX  the invention.
XX  Sequence 251 AA;
XX  Query Match      87.2%; Score 1089.5; DB 5; Length 251;
XX  Best Local Similarity 83.6%; Pred. No. 1.7e-69;
XX  Matches 209; Conservative 14; Mismatches 16; Indels 11; Gaps 2;
XX  QY      1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSYSSMSVWRQAPGKLEWVAIVSYDGSNKYY 60
XX  Db      1 QITLKEGGGVQPGERSLRSLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
XX  QY      61 ADSVKGRFTISRDNKNTLYLQMSLRADTAIVYCARDR-----YFDLWGRGTL 110
XX  Db      61 ADSVKGRFTVSRDNKNTLYLQMSLRADTAIVYCARDR-----YFDLWGRGTL 110
XX  QY      111 VTSSGGGGGGGGGGGGGSGGSGSALTQPASVSGSPQSGTITISGLQAEDEADYYCSSF-ANSGPL 229
XX  Db      121 VTSSGGGGGGGGGGGGGSGGSGSALTQPASVSGSPQSGTITISGLQAEDEADYYCSSF-ANSGPL 229
XX  QY      171 YPGKAPKLLIYDVSNRPGISNRFSGSKSGTASLTISGLQAEDEADYYCSSF-ANSGPL 229
XX  Db      181 HPGKAPKLLIYEGSKRPGVSNRFGSKSGTASLTISGLQAEDEADYYCSSF-ANSGPL 229
XX  QY      230 FGGGTRKTVTL 239
XX  Db      241 FGGGTRKTVL 250
XX  RESULT 10
XX  ABP45103
XX  ID ABP45103 standard; protein; 251 AA.

```

X DB ABP45103;
 X 19-AUG-2002 (first entry)
 X Human BlyS binding scFv SEQ ID 1114.
 W BlyS; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
 W tumour necrosis factor; B cell proliferation; B cell differentiation;
 W immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
 W antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
 W systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
 W common variable immunodeficiency; acquired immunodeficiency syndrome.
 X Homo sapiens.
 X ABP44992 standard; protein; 253 AA.
 X AC ABP44992;
 X XX
 X 10-JAN-2002.
 X 15-JUN-2001; 2001WO-US019110.
 X 15-JUN-2000; 2000US-0212210P.
 X 17-OCT-2000; 2000US-0240816P.
 X 16-MAR-2001; 2001US-0276248P.
 X 21-MAR-2001; 2001US-0277379P.
 X 25-MAY-2001; 2001US-0293499P.
 X (HUMA-) HUMAN GENOME SCI INC.
 X (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
 X Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
 X WPI; 2002-114799/15.
 X Antibodies against B Lymphocyte Stimulating polypeptides, useful for the
 X diagnosis and treatment of cancers and immune disorders.
 X Claim 1; Page 1731-1732; 3148pp; English.
 X This invention describes novel antibodies that immunospecifically bind to
 X B Lymphocyte Stimulator (BlyS) polypeptides. BlyS is a member of the
 X tumour necrosis factor (TNF) super family and induces B cell
 X proliferation and differentiation. The antibodies of the invention have
 X cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
 X antirheumatic and antiAIDS activity and can be used in vaccines to
 X inhibit the expression and activity of BlyS. The antibodies bind to BlyS
 X and so may be used to detect and quantitate the presence of BlyS in
 X biological samples and may be used in this way to diagnose disease
 X associated with aberrant expression of BlyS. They may also be
 X administered to treat diseases associated with aberrant BlyS expression
 X and activity such as cancer, immune, and autoimmune disorders and
 X diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
 X immunodeficiency (e.g. common variable immunodeficiency (CVID) and
 X acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
 X the antibodies and fragments of the antibodies described in the method of
 X the invention
 X Sequence 251 AA;
 X Query Match 87.1%; Score 1088.5; DB 5; Length 251;
 X Best Local Similarity 83.2%; Pred. No. 2e-69;
 X Matches 208; Conservative 16; Mismatches 15; Indels 11; Gaps 2;
 X 1 QVCLQESGGGLVPGGSLRLSCAAGGFFPSVSNMWRQAPGKLEWVAIVSYDGSNKYY 60
 X 1 EVQLVESGGGVQPGGSLRLSCAAGFTVYAMHWVRQAPGKGLQWVAIVSYDGSNKYY 60
 X 61 ADSVKGRFTISRDNSKNTLYLQWNSLRADTAIVYICARDR-----YFDLWGRGTL 110
 X 61 ADSVKGRFTVSRDNSKNTLYLQWNSLRADTAIVYICARSHYDILTGLNYWYFDLWGGTT 120
 X 111 VTVSSGGGGGGGGGGGSGSGLTQPSVSGSPQSGITISCTGTSSDVCGYNYVSWYQQ 170

DB 121 VTVSSGGGGGGGGGGGSGSGLTQPSVSGSPQSGITISCTGTSSDVCGYNYVSWYQQ 180
 QY 171 YPGKAPKLLIYDVNRPSTGINSRPSGSKSDTASLTISGLQADEADYYCSSF-ANSGPL 229
 DB 181 HPGKAPKLLIYEGSKRPSTGINSRPSGSKSDTASLTISGLQADEADYYCSSYTRSTRV 240
 QY 230 FGGGKVTVL 239
 DB 241 FGGGKVTVL 250
 RESULT 11
 ABP44992
 ID ABP44992 standard; protein; 253 AA.
 X AC ABP44992;
 X XX
 X 19-AUG-2002 (first entry)
 X XX
 X Human BlyS binding scFv SEQ ID 1003.
 X DE
 X XX
 X BlyS; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
 X tumour necrosis factor; B cell proliferation; B cell differentiation;
 X immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
 X antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
 X systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
 X common variable immunodeficiency; acquired immunodeficiency syndrome.
 X Homo sapiens.
 X OS
 X WO200202641-A1.
 X XX
 X 10-JAN-2002.
 X 15-JUN-2001; 2001WO-US019110.
 X 16-JUN-2000; 2000US-0212210P.
 X 17-OCT-2000; 2000US-0240816P.
 X 16-MAR-2001; 2001US-0276248P.
 X 21-MAR-2001; 2001US-0277379P.
 X 25-MAY-2001; 2001US-0293499P.
 X (HUMA-) HUMAN GENOME SCI INC.
 X (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
 X Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
 X WPI; 2002-114799/15.
 X Antibodies against B Lymphocyte Stimulating polypeptides, useful for the
 X diagnosis and treatment of cancers and immune disorders.
 X Claim 1; Page 1598-1599; 3148pp; English.
 X This invention describes novel antibodies that immunospecifically bind to
 X B Lymphocyte Stimulator (BlyS) polypeptides. BlyS is a member of the
 X tumour necrosis factor (TNF) super family and induces B cell
 X proliferation and differentiation. The antibodies of the invention have
 X cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
 X antirheumatic and antiAIDS activity and can be used in vaccines to
 X inhibit the expression and activity of BlyS. The antibodies bind to BlyS
 X and so may be used to detect and quantitate the presence of BlyS in
 X biological samples and may be used in this way to diagnose disease
 X associated with aberrant expression of BlyS. They may also be
 X administered to treat diseases associated with aberrant BlyS expression
 X and activity such as cancer, immune, and autoimmune disorders and
 X diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
 X immunodeficiency (e.g. common variable immunodeficiency (CVID) and
 X acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
 X the antibodies and fragments of the antibodies described in the method of
 X the invention

SQ Sequence 253 AA;
 Query Match 86.8%; Score 1084.5; DB 5; Length 253;
 Best Local Similarity 82.9%; Pred. No. 3.9e-69;
 Matches 209; Conservative 14; Mismatches 16; Indels 13; Gaps 2;
 QY 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSSYSMSWVRQAPGKLEWVAIVSYDGSNKYY 60
 DB 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSSYSMSWVRQAPGKLEWVAIVSYDGSNKYY 60
 QY 61 ADSVKGRFTISRDNKNTLYLQNSLRADDTAVYICARDVFDL-----WGRG 108
 DB 61 VDSVKGRFTISRDNKNTLYLQNSLRADDTAVYICARDVFDL-----WGRG 108
 QY 109 TLVTSSGGGGGGGGGGGGGSGGSGSALTQTPASVSGSPGQSIITISCTGTSDDIGAYNTVSWY 168
 DB 121 TLVTSSGGGGGGGGGGGGGSGGSGSALTQTPASVSGSPGQSIITISCTGTSDDIGAYNTVSWY 180
 QY 169 QVPGKAPKLLIYDVSNRPSGISNRPSGSGSGDTSALTISGLQAEDEADYICSSP-ANSG 227
 DB 181 QVPGKAPKLLIYDVSNRPSGISNRPSGSGSGDTSALTISGLQAEDEADYICSSP-ANSG 240
 QY 228 PLFGGGTKVTVL 239
 DB 241 RVFGGGTKVTVL 252
 RESULT 12
 ABP45321
 ID ABP45321 standard; protein; 251 AA.
 AC ABP45321;
 XX
 DT 19-AUG-2002 (first entry)
 XX
 DE Human BlyS binding scFv SEQ ID 1332.
 XX
 KW BlyS; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
 KW tumour necrosis factor; B cell proliferation; B cell differentiation;
 KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
 KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
 KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
 KW common variable immunodeficiency; acquired immunodeficiency syndrome.
 XX
 OS Homo sapiens.
 XX
 PN WC200202641-A1.
 XX
 PD 10-JAN-2002.
 XX
 PF 15-JUN-2001; 2001WO-US019110.
 XX
 PR 16-JUN-2000; 2000US-0212210P.
 PR 17-OCT-2000; 2000US-0240816P.
 PR 16-MAR-2001; 2001US-0276248P.
 PR 21-MAR-2001; 2001US-0277379P.
 PR 25-MAY-2001; 2001US-0293499P.
 XX
 PA (HUMA-) HUMAN GENOME SCI INC.
 PA (CAME-) CAMBRIDGE ANTIBODY TECHNOLOGY.
 XX
 XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
 PI WPI; 2002-114799/15.
 DR
 XX
 PT Antibodies against B Lymphocyte Stimulating polypeptides, useful for the
 PT diagnosis and treatment of cancers and immune disorders.
 XX
 PS Claim 1; Page 1992-1993; 3148pp; English.
 PS
 XX This invention describes novel antibodies that immunospecifically bind to
 CC B Lymphocyte Stimulator (BlyS) polypeptides. BlyS is a member of the
 CC tumour necrosis factor (TNF) super family and induces B cell

CC proliferation and differentiation. The antibodies of the invention have
 CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
 CC antirheumatic and antiAIDS activity and can be used in vaccines to
 CC inhibit the expression and activity of BlyS. The antibodies bind to BlyS
 CC and so may be used to detect and quantitate the presence of BlyS in
 CC biological samples and may be used in this way to diagnose disease
 CC associated with aberrant expression of BlyS. They may also be
 CC administered to treat diseases associated with aberrant BlyS expression
 CC and activity such as cancer, immune, and autoimmune disorders and
 CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis, and
 CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
 CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
 CC the antibodies and fragments of the antibodies described in the method of
 CC the invention
 XX
 SQ Sequence 251 AA;
 Query Match 86.6%; Score 1082.5; DB 5; Length 251;
 Best Local Similarity 83.4%; Pred. No. 5.4e-69;
 Matches 208; Conservative 14; Mismatches 17; Indels 11; Gaps 2;
 QY 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSSYSMSWVRQAPGKLEWVAIVSYDGSNKYY 60
 DB 1 EVQLVQSGGGVQVPGSRSLRLSCAASGFTFSSYSMSWVRQAPGKLEWVAIVSYDGSNKYY 60
 QY 61 ADSVKGRFTISRDNKNTLYLQNSLRADDTAVYICARDR-----YEDLWGRGTL 110
 DB 61 ADSVKGRFTISRDNKNTLYLQNSLRADDTAVYICARDR-----YEDLWGRGTL 120
 QY 111 VTSSGGGGGGGGGGGGGSGGSGSALTQTPASVSGSPGQSIITISCTGTSDDIGAYNTVSWY 170
 DB 121 VTSSGGGGGGGGGGGGGSGGSGSALTQTPASVSGSPGQSIITISCTGTSDDIGAYNTVSWY 180
 QY 171 YPGKAPKLLIYDVSNRPSGISNRPSGSGSGDTSALTISGLQAEDEADYICSSP-ANSGPL 229
 DB 181 HPGKAPKLLIYDVSNRPSGISNRPSGSGSGDTSALTISGLQAEDEADYICSSP-ANSGPL 240
 QY 230 FGGGTRKTVL 239
 DB 241 FGGGTRKTVL 250
 RESULT 13
 ABP45690
 ID ABP45690 standard; protein; 254 AA.
 XX
 AC ABP45690;
 XX
 DT 19-AUG-2002 (first entry)
 XX
 DE Human BlyS binding scFv SEQ ID 1701.
 XX
 KW BlyS; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
 KW tumour necrosis factor; B cell proliferation; B cell differentiation;
 KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
 KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
 KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
 KW common variable immunodeficiency; acquired immunodeficiency syndrome.
 XX
 OS Homo sapiens.
 XX
 PN WC200202641-A1.
 XX
 PD 10-JAN-2002.
 XX
 PF 15-JUN-2001; 2001WO-US019110.
 XX
 PR 16-JUN-2000; 2000US-0212210P.
 PR 17-OCT-2000; 2000US-0240816P.
 PR 16-MAR-2001; 2001US-0276248P.
 PR 21-MAR-2001; 2001US-0277379P.
 PR 25-MAY-2001; 2001US-0293499P.
 XX

(HUMA-) HUMAN GENOME SCI INC.
 (CAME-) CAMBRIDGE ANTIBODY TECHNOLOGY.
 Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
 WPI; 2002-114799/15.
 Antibodies against B Lymphocyte Stimulating polypeptides, useful for the
 diagnosis and treatment of cancers and immune disorders.
 Claim 1; Page 2432-2433; 3148pp; English.
 This invention describes novel antibodies that immunospecifically bind to
 B Lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
 tumour necrosis factor (TNF) super family and induces B cell
 proliferation and differentiation. The antibodies of the invention have
 cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
 antirheumatic and antiAIDS activity and can be used in vaccines to
 inhibit the expression and activity of Blys. The antibodies bind to Blys
 and so may be used to detect and quantitate the presence of Blys in
 biological samples and may be used in this way to diagnose disease
 associated with aberrant expression of Blys. They may also be
 administered to treat diseases associated with aberrant Blys expression
 and activity such as cancer, immune, and autoimmune disorders and
 diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
 immunodeficiency (e.g. common variable immunodeficiency (CVID) and
 acquired immunodeficiency syndrome (AIDS)). ABP4390-ABP4728 represent
 the antibodies and fragments of the antibodies described in the method of
 the invention
 SQ Sequence 254 AA;
 Query Match 86.3%; Score 1079; DB 5; Length 254;
 Best Local Similarity 81.8%; Pred. No. 9.7e-69;
 Matches 207; Conservative 18; Mismatches 14; Indels 14; Gaps 2;
 QY 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSYMSWVRQAPGKLEWAVISYDGSNKYY 60
 DB 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSYMSWVRQAPGKLEWVAISYDGSNKYY 60
 QY 61 ADSVKGRFTISRDNKNTLYLQNSLRADETAVYICARDRYF-----DLWGR 107
 DB 61 ADSVKGRFTISRDNKNTLYLQNSLRADETAVYICARDRYF-----DLWGR 107
 QY 108 GTLVTVSSGGGGSGGGSGGGSQSALTPASVSGSPGQSITISCTGTSSDYGAYNVSW 167
 DB 121 GTMTVTSSGGGGSGGGSGGGSQSALTPASVSGSPGQSITISCTGTSSDYGAYNVSW 167
 QY 168 YQOYPGKAPKLLIYDVSNRPSGISNRFSGSKGSDTASLTISGLQAEDEADYICSSP-ANS 226
 DB 181 YQOHPGKAPKLLMIYEGSKRPSGVSNRPSGSKSGNTASLTISGLQAEDEADYICSSYTRRS 240
 QY 227 GFLFGGKTKTVL 239
 DB 241 TRVFGGKTKTVL 253
 RESULT 14
 ABP45748
 ID ABP45748 standard; protein; 254 AA.
 AC ABP45748;
 XX 19-AUG-2002 (first entry)
 DT Human Blys binding scfv SEQ ID 1759.
 DE Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
 KW tumour necrosis factor; B cell proliferation; B cell differentiation;
 KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
 KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
 KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
 KW common variable immunodeficiency; acquired immunodeficiency syndrome.

XX Homo sapiens.
 OS WO200202641-A1.
 XX 10-JAN-2002.
 XX 15-JUN-2001; 2001WO-US019110.
 XX 16-JUN-2000; 2000US-0212210P.
 PR 17-OCT-2000; 2000US-0240816P.
 PR 16-MAR-2001; 2001US-0276248P.
 PR 21-MAR-2001; 2001US-0277379P.
 PR 25-MAY-2001; 2001US-0293499P.
 XX (HUMA-) HUMAN GENOME SCI INC.
 (CAME-) CAMBRIDGE ANTIBODY TECHNOLOGY.
 Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
 WPI; 2002-114799/15.
 PT Antibodies against B Lymphocyte Stimulating polypeptides, useful for the
 diagnosis and treatment of cancers and immune disorders.
 XX Claim 1; Page 2501-2502; 3148pp; English.
 PS This invention describes novel antibodies that immunospecifically bind to
 B Lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
 tumour necrosis factor (TNF) super family and induces B cell
 proliferation and differentiation. The antibodies of the invention have
 cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
 antirheumatic and antiAIDS activity and can be used in vaccines to
 inhibit the expression and activity of Blys. The antibodies bind to Blys
 and so may be used to detect and quantitate the presence of Blys in
 biological samples and may be used in this way to diagnose disease
 associated with aberrant expression of Blys. They may also be
 administered to treat diseases associated with aberrant Blys expression
 and activity such as cancer, immune, and autoimmune disorders and
 diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
 immunodeficiency (e.g. common variable immunodeficiency (CVID) and
 acquired immunodeficiency syndrome (AIDS)). ABP4390-ABP4728 represent
 the antibodies and fragments of the antibodies described in the method of
 the invention
 SQ Sequence 254 AA;
 Query Match 86.3%; Score 1079; DB 5; Length 254;
 Best Local Similarity 82.2%; Pred. No. 9.7e-69;
 Matches 208; Conservative 16; Mismatches 15; Indels 14; Gaps 2;
 QY 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSYMSWVRQAPGKLEWAVISYDGSNKYY 60
 DB 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSYMSWVRQAPGKLEWAVISYDGSNKYY 60
 QY 61 ADSVKGRFTISRDNKNTLYLQNSLRADETAVYICARDRYF-----DLWGR 107
 DB 61 ADSVKGRFTISRDNKNTLYLQNSLRADETAVYICARDRYF-----DLWGR 107
 QY 108 GTLVTVSSGGGGSGGGSGGGSQSALTPASVSGSPGQSITISCTGTSSDYGAYNVSW 167
 DB 121 GTMTVTSSGGGGSGGGSGGGSQSALTPASVSGSPGQSITISCTGTSSDYGAYNVSW 167
 QY 168 YQOYPGKAPKLLIYDVSNRPSGISNRFSGSKGSDTASLTISGLQAEDEADYICSSP-ANS 226
 DB 181 YQOHPGKAPKLLMIYEGSKRPSGVSNRPSGSKSGNTASLTISGLQAEDEADYICSSYTRRS 240
 QY 227 GFLFGGKTKTVL 239
 DB 241 TRVFGGKTKTVL 253
 RESULT 15

[REDACTED]

GenCore version 5.1.6
Copyright (C) 1993 - 2004 CompuGen Ltd.

DM protein - protein search, using sw model

Run on: March 15, 2004, 07:25:43 ; Search time 22 Seconds
(without alignments)
560.846 Million cell updates/sec

Title: US-09-620-955B-6
Perfect score: 1250
Sequence: 1 QVQLQSGGGLVPGGSLRL.....CSFANSGLFPGGKTIVTL 239

Scoring table: BLOSUM62
Gapop 10:0, Gapext 0.5

Searched: 389414 seqs, 51625971 residues

Total number of hits satisfying chosen parameters: 389414

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents AA.*
1: /cgn2_6/ptodata/2/iaa/5A COMB.pep.*
2: /cgn2_6/ptodata/2/iaa/5B COMB.pep.*
3: /cgn2_6/ptodata/2/iaa/6A COMB.pep.*
4: /cgn2_6/ptodata/2/iaa/6B COMB.pep.*
5: /cgn2_6/ptodata/2/iaa/PTCUS COMB.pep.*
6: /cgn2_6/ptodata/2/iaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query	Score	Match	Length	ID	Description
1	1015.5	81.2	310	4	US-09-079-029-11	Sequence 11, Appl
2	906	72.5	244	4	US-08-918-148-79	Sequence 79, Appl
3	902.5	72.2	312	4	US-09-079-029-10	Sequence 10, Appl
4	897.5	71.8	249	4	US-10-039-785-53	Sequence 53, Appl
5	860.5	68.8	249	4	US-08-918-148-74	Sequence 74, Appl
6	860	68.8	309	4	US-09-079-029-9	Sequence 9, Appl
7	855.5	68.4	334	4	US-09-646-028-53	Sequence 53, Appl
8	855.5	68.4	339	4	US-09-646-028-55	Sequence 55, Appl
9	855.5	68.4	348	4	US-09-646-028-51	Sequence 51, Appl
10	850.5	68.0	245	4	US-10-039-785-43	Sequence 43, Appl
11	839.5	67.2	245	4	US-10-039-785-47	Sequence 47, Appl
12	839.5	67.2	245	4	US-10-039-785-51	Sequence 51, Appl
13	838.5	67.1	245	4	US-08-918-148-75	Sequence 75, Appl
14	837.5	67.0	245	4	US-08-918-148-76	Sequence 76, Appl
15	836.5	66.9	245	4	US-08-918-148-78	Sequence 78, Appl
16	834.5	66.8	245	4	US-10-039-785-52	Sequence 52, Appl
17	830.5	66.4	245	4	US-10-039-785-46	Sequence 46, Appl
18	829.5	66.4	245	4	US-10-039-785-42	Sequence 42, Appl
19	829.5	66.4	245	4	US-10-039-785-45	Sequence 45, Appl
20	820.5	65.6	245	4	US-10-039-785-49	Sequence 49, Appl
21	817.5	65.4	280	3	US-09-260-527-1	Sequence 1, Appl
22	817.5	65.4	281	4	US-09-028-769B-178	Sequence 178, App
23	815	65.2	244	4	US-08-918-148-77	Sequence 77, Appl
24	808.5	64.7	245	4	US-10-039-785-48	Sequence 48, Appl
25	785	62.8	236	2	US-08-190-199A-65	Sequence 65, Appl
26	782	62.6	255	4	US-09-553-498-8	Sequence 8, Appl
27	782	62.6	255	4	US-09-618-869-8	Sequence 8, Appl

28	775.5	62.0	258	2	US-08-665-202-5	Sequence 5, Appl
29	775.5	62.0	258	4	US-09-315-574-5	Sequence 5, Appl
30	773.5	61.9	284	3	US-08-564-164A-2	Sequence 2, Appl
31	773	61.8	240	2	US-08-956-047-25	Sequence 25, Appl
32	770	61.6	301	2	US-08-661-052-14	Sequence 14, Appl
33	770	61.6	301	3	US-03-188-082-14	Sequence 14, Appl
34	770	61.6	301	4	US-09-364-088-14	Sequence 14, Appl
35	770	61.6	301	4	US-09-102-716-14	Sequence 16, Appl
36	770	61.6	553	2	US-08-661-052-16	Sequence 16, Appl
37	770	61.6	553	3	US-09-188-082-16	Sequence 16, Appl
38	770	61.6	553	4	US-09-364-088-16	Sequence 16, Appl
39	770	61.6	553	4	US-09-102-716-16	Sequence 10, Appl
40	757.5	60.6	282	2	US-08-860-174A-10	Sequence 148, App
41	754.5	60.4	240	1	US-08-488-113B-148	Sequence 148, App
42	754.5	60.4	240	1	US-08-477-484B-148	Sequence 148, App
43	754.5	60.4	240	2	US-08-646-360-148	Sequence 148, App
44	754.5	60.4	240	3	US-08-839-765-148	Sequence 148, App
45	754.5	60.4	240	3	US-09-136-389-148	Sequence 148, App

ALIGNMENTS

RESULT 1
US-09-079-029-11
; Sequence 11, Application US/09079029
; Patent No. 6342369
; GENERAL INFORMATION:
; APPLICANT: Adams, Camilla W.
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Chuntharapai, Anan
; APPLICANT: Kim, Kyung J.
; TITLE OF INVENTION: Apo-2 Receptor
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESS: Genentech, Inc.
; STREET: 1 DNA Way
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Winpatin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/079,029
; Filing Date:
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Marschang, Diane L.
; REGISTRATION NUMBER: 35,600
; REFERENCE/DOCKET NUMBER: P1101R2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650/225-5416
; TELEFAX: 650/952-9881
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 310 amino acids
; TYPE: Amino Acid
; TOPOLOGY: Linear

Query Match 81.2%; Score 1015.5; DB 4; Length 310;
Best Local Similarity 80.7%; Pred. No. 1.1e-68;
Matches 197; Conservative 16; Mismatches 26; Indels 5; Gaps 2;

Qy	1	QVQLQSGGGLVPGGSLRLCAASGFTFSSYSMSGVRQAPCGKLEWAVISYDGSNKYY 60
Db	40	QVQLVSGGGLVPGGSLRLCAASGFTFSSYSMSGVRQAPCGKLEWAVISYDGSNKYY 99
Qy	61	ADSVKGRFTISRDNSKNTLYLQNSLRLEADTAVTYCARDR---YFDLWGRGLTVTVSSGG 117

Db 100 ADVKGRFTISRDNSKNTLYLQNSLRADTAVYCARDRGYYNDVWKGKTTTVSSGG 159
QY 118 GSGGGGGGQSALTQPAVSQSPGQITISCTGSSDYGAYNVSWYQVPGKAPK 177
Db 160 GSGGGGGGQSALTQPPVSGAPGQVITISCTGRSSNIGAGHDVHWYQULPGTAPK 219
QY 178 LLIYDVSNRPSGISNRFSGKSGDTSALTISGLQADEADYYCSSFANS--GPIFGGGTK 235
Db 220 LLIYDNRPSGVPDRFSGSRGTSASLTITGLQADEADYYCQSDSLRGSVFGGJK 279
QY 236 VTVL 239
Db 280 VTVL 283

RESULT 2
US-08-918-148-79
; Sequence 79, Application US/08918148A
; Patent No. 6342220
; GENERAL INFORMATION:
; APPLICANT: Adams, Camellia
; APPLICANT: W.
; APPLICANT: Carter, Paul J.
; APPLICANT: Fendly, Brian M.
; APPLICANT: Gurney, Austin L.
; TITLE OF INVENTION: Agonist Antibodies
; FILE REFERENCE: P0979
; CURRENT APPLICATION NUMBER: US/08/918,148A
; CURRENT FILING DATE: 1997-08-25
; NUMBER OF SEQ ID NOS: 79
; SEQ ID NO 79
; LENGTH: 244
; TYPE: PRT
; ORGANISM: artificial
US-08-918-148-79

Query Match 72.5%; Score 906; DB 4; Length 244;
Best Local Similarity 72.5%; Pred. No. 1.3e-60;
Matches 174; Conservative 24; Mismatches 40; Indels 2; Gaps 2;
QY 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFFSSYSMSWRQAPGKLEWAVISYDQSNKY 60
Db 3 QVQLQESGGGLVQPGGSLRLSCAASGFTFFSSYSMSWRQAPGKLEWAVISYDQSNKY 61
QY 61 ADSVKGRTISRDNSKNTLYLQNSLRADTAVYCARDYFDLWGRGTLTVYSSGGGS 120
Db 62 NPSLSRVTISVTSKQFSLKSSVTAADTAVYCARGFYFDVWGRGTMTVYSSGGGS 121
QY 121 GGGGGGGGQSALTQPAVSQSPGQITISCTGSSDYGAYNVSWYQVPGKAPKLI 180
Db 122 GGGGGGGGQSALTQPPVSGAPGQVITISCTGRSSNIGAGHDVHWYQULPGTAPK 181
QY 181 YDVSNRPSGISNRFSGKSGDTSALTISGLQADEADYYCSSF--ANSGPLFGGKTVTL 239
Db 182 YEGSKRPSGVNRFSGKSGDTSALTISGLQADEADYYCSSF--ANSGPLFGGKTVTL 241

RESULT 3
US-09-079-029-10
; Sequence 10, Application US/09079029
; Patent No. 6342369
; GENERAL INFORMATION:
; APPLICANT: Adams, Camellia W.
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Chuntharapai, Anan
; APPLICANT: Kim, Kyung J.
; TITLE OF INVENTION: App-2 Receptor
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 1 DNA Way
; CITY: South San Francisco

STATE: California
COUNTRY: USA
ZIP: 94080
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WinPatIn (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/079,029
FILING DATE:
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Marechang, Diane L.
REGISTRATION NUMBER: 55,600
REFERENCE/DOCKET NUMBER: P1101R2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/225-5416
TELEFAX: 650/952-9881
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 312 amino acids
TYPE: Amino Acid
TOPOLOGY: Linear
US-09-079-029-10
Query Match 72.2%; Score 902.5; DB 4; Length 312;
Best Local Similarity 73.9%; Pred. No. 3.1e-60;
Matches 184; Conservative 20; Mismatches 30; Indels 15; Gaps 5;
QY 2 VQLQESGGGLVQPGGSLRLSCAASGFTFFSSYSMSWRQAPGKLEWAVISYDQSNKY 61
Db 41 VQLVESGGGLVQPGGSLRLSCAASGFTFFSSYSMSWRQAPGKLEWAVISYDQSEKIYV 100
QY 62 DSVKGRFTISRDNSKNTLYLQNSLRADTAVYCARD-----RYFDLWGRGTLTV 112
Db 101 DSVKGRFTISRDNAKNSLYLQNSLRADTAVYCARDLLKVKSSSGWFDPMGRGTTVT 160
QY 113 VSSGGGGGGGSGGSGQSALTQPAVSQSPGQITISCTGSSDYGAYNVSWYQV 172
Db 161 VSSGGGGGGGSGGSGGS--SELTODPAVSVALGQTVITCQDGS--LRSY-YASWYQKP 216
QY 173 GKAPKLIYDVSNRPSGISNRFSGKSGDTSALTISGLQADEADYYCSSFANS--PLF 230
Db 217 GQAPVLIYGNRPSGIPDRFSGSSSGNTASLTITGAQADEADYYCNSRDSNGHVV 276
QY 231 GGGTKVTVL 239
Db 277 GGGTKLTVL 285

RESULT 4
US-10-039-785-53
; Sequence 53, Application US/10039785
; Patent No. 6538938
; GENERAL INFORMATION:
; APPLICANT: Salcedo et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to TRAIL
; TITLE OF INVENTION: Receptors
; FILE REFERENCE: PF550
; CURRENT APPLICATION NUMBER: US/10/039,785
; CURRENT FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: 60/369,860
; PRIOR FILING DATE: 2002-04-05
; PRIOR APPLICATION NUMBER: 60/341,237
; PRIOR FILING DATE: 2001-12-20
; PRIOR APPLICATION NUMBER: 60/331,310
; PRIOR FILING DATE: 2001-11-14
; PRIOR APPLICATION NUMBER: 60/331,044
; PRIOR FILING DATE: 2001-11-07
; PRIOR APPLICATION NUMBER: 60/327,364
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/323,807

;; PRIOR FILING DATE: 2001-09-21
;; PRIOR APPLICATION NUMBER: 60/309,176
;; PRIOR FILING DATE: 2001-08-02
;; PRIOR APPLICATION NUMBER: 60/294,981
;; PRIOR FILING DATE: 2001-06-04
;; PRIOR APPLICATION NUMBER: 60/293,473
;; PRIOR FILING DATE: 2001-05-25
;; NUMBER OF SEQ ID NOS: 66
;; SOFTWARE: Patent in Ver. 2.1
;; SEQ ID NO 53
;; LENGTH: 249
;; TYPE: PRT
;; ORGANISM: Artificial sequence
;; FEATURE:
;; OTHER INFORMATION: T1006F07 scFv
US-10-039-785-53

Query Match 71.8%; Score 897.5; DB 4; Length 249;
Best Local Similarity 72.1%; Pred. No. 5.6e-60;
Matches 181; Conservative 21; Mismatches 34; Indels 15; Gaps 4;
QY 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSSYSMSVWRQAPGKGLWVAVISYDGSNKYY 60
DB 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYSMSVWRQAPGKGLWVAVISYDGSNKYY 60
QY 61 ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYICARDRYF-----DLWGRGTL 110
DB 61 ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYICAREPSPQNGHYSYGMDVWGQGTW 120
QY 111 VTVSSGGGGGGGGGGGAS-QSALTQPASVSGSPQSGITISCTGTSDDIGAYNYVSWYQ 169
DB 121 VTVSSGGGGGGGGGSAQSGLTQPPSVSPGQAARITCSG---DKLGDKYASWYQ 177
QY 170 QYFGKAPKLLIYDVNRPISNRPFGSKSGTASLTISGLQAEDEADYICSSPANSFGP- 228
DB 178 QRPGQSPVLIYQDNKRPSGIPERFSGNSGNTATLKISGTQAMDEADYICLAWDSADW 237
QY 229 LFGGGTKVTVL 239
DB 238 VFGGGTKVTVL 248

RESULT 5

US-08-918-148-74
;; Sequence 74, Application US/08918148A
;; Patent No. 6342220
;; GENERAL INFORMATION:
;; APPLICANT: Adams, Camellia
;; APPLICANT: W.
;; APPLICANT: Carter, Paul J.
;; APPLICANT: Fendly, Brian M.
;; APPLICANT: Gurney, Austin L.
;; TITLE OF INVENTION: Agonist Antibodies
;; FILE REFERENCE: P0979
;; CURRENT FILING DATE: 1997-08-25
;; NUMBER OF SEQ ID NOS: 79
;; SEQ ID NO 74
;; LENGTH: 249
;; TYPE: PRT
;; ORGANISM: artificial
US-08-918-148-74

Query Match 69.8%; Score 860.5; DB 4; Length 249;
Best Local Similarity 68.0%; Pred. No. 3.3e-57;
Matches 166; Conservative 33; Mismatches 40; Indels 5; Gaps 2;
QY 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSSYSMSVWRQAPGKGLWVAVISYDGSNKYY 60
DB 3 QVQLQESGGEMKPKGSLKISCKGYSPATSWIGWRQMPGRLGWVAVIMYPGNSDTRH 62
QY 61 ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYICAR-----DRYFDLWGRGTLVTVSSG 116

DB 63 NPSFEDQVTMSADTGTINTAYLQWSSLKASDRTAMYCARAGVAGGAFDLMGKGTWTVTVSSG 122
QY 117 GSGSGGGGGGGGSSALATQPASVSGSPQSGITISCTGTSDDIGAYNYVSWYQYVPGKAP 176
DB 123 GSGSGGGGGGGGSSQSVLTQPASVSGSPQSGITISCTGTSDDIGAYNYVSWYQYVPGKAP 182
QY 177 KLLIYDVNRPISNRPFGSKSGTASLTISGLQAEDEADYICSSPANSFG-PLFGGGTK 235
DB 183 KLLIYGNRNRPISNRPFGSDRFSASKSGNTASLTISGLQAEDEADYICSTYAPPGIIMFGGGTK 242
QY 236 VTVL 239
DB 243 LTVL 246

RESULT 6

US-09-079-029-9
;; Sequence 9, Application US/09079029
;; Patent No. 6342369
;; GENERAL INFORMATION:
;; APPLICANT: Adams, Camillia W.
;; APPLICANT: Ashkenazi, Avi J.
;; APPLICANT: Chuntharapai, Anan
;; APPLICANT: Kim, Kyung J.
;; TITLE OF INVENTION: Apo-2 Receptor
;; NUMBER OF SEQUENCES: 14
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Genentech, Inc.
;; STREET: 1 DNA Way
;; CITY: South San Francisco
;; STATE: California
;; COUNTRY: USA
;; ZIP: 94080
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: WinPatIn (Genentech)
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/079,029
;; FILING DATE:
;; CLASSIFICATION:
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Marschang, Diane L.
;; REGISTRATION NUMBER: 35,600
;; REFERENCE/DOCKET NUMBER: P1101R2
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 650/225-5416
;; TELEFAX: 650/952-9881
;; INFORMATION FOR SEQ ID NO: 9:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 309 amino acids
;; TYPE: Amino Acid
;; TOPOLOGY: Linear
US-09-079-029-9

Query Match 68.8%; Score 860; DB 4; Length 309;
Best Local Similarity 70.0%; Pred. No. 4.6e-57;
Matches 173; Conservative 29; Mismatches 33; Indels 12; Gaps 5;
QY 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSSYSMSVWRQAPGKGLWVAVISYDGSNKYY 60
DB 40 EVQLVQSGGVERPGGSLRLSCAASGFTFDYGMVWRQAPGKGLWVSGINWNGSGTY 99
QY 61 ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYICAR-----RDYFDLWGRGTLVTVS 114
DB 100 ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYICAKILQAGRWTFDLWNGKTVTVS 159
QY 115 GSGSGGGGGGGGSSALTPASVSGSPQSGITISCTGTSDDIGAYNYVSWYQYVPGK 174
DB 160 SGGSGGGGGGGGGGSS-SELTQDPASVALGQTVRITCGDS--LRSY-YASWYQKPGQ 215
QY 175 APLKLLIYDVNRPISNRPFGSKSGTASLTISGLQAEDEADYICSSPANSFG-PLFGG 232

Db 216 APVLVIYGNRPSPGIPDRFGSSGNTASLTITGAQAEADYICNSRDSSGHHVFG 275
QY 233 GTKVTVL 239
Db 276 GTKLTVL 282

RESULT 7
US-09-646-028-53
; Sequence 53, Application US/09646028
; Patent No. 6562347
; GENERAL INFORMATION:
; APPLICANT: Kwak, Larry
; APPLICANT: Biragyn, Arya
; TITLE OF INVENTION: METHODS AND COMPOSITIONS OF
; TITLE OF INVENTION: CHEMOKINE-TUMOR ANTIGEN FUSION PROTEINS AS CANCER VACCINES
; FILE REFERENCE: 14014.0316/P
; CURRENT APPLICATION NUMBER: US/09/646,028
; CURRENT FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 60/077,745
; PRIOR FILING DATE: 1998-03-12
; NUMBER OF SEQ ID NOS: 57
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 53
; LENGTH: 334
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of artificial sequence./note=synthetic construct
US-09-646-028-53

Query Match 68.4%; Score 855.5; DB 4; Length 334;
Best Local Similarity 69.0%; Pred. No. 1.1e-56;
Matches 171; Conservative 29; Mismatches 39; Indels 9; Gaps 4;
QY 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSYSSMSVWRQAPGKLEWAVISYDGSNKYY 60
Db 80 EVQLLESGLVQSGGSLRLSCVASGLTFSSTAITWVRQAPGKLEWVSGISFGDTTYY 139
QY 61 ADSVKGRFTISRDNKNTLYLQNNLSLAEDTAVYYCARDR----YFDLWGRGTLTVSS- 115
Db 140 ADSVKGRFSASRDNSKNTVYLQNNLRPNDAVYFCANNTGNFCLDNWGQGLTVTVSSR 199
QY 116 GGGSGGGGGGG--GSQSALTQPSVSGSGSDTASLTISGLQAEADY--CSSFANSGLPG 173
Db 200 GGGSGGGGGGGSGGSGSVLTQPPSVSAAPGQRVTISCTGSRNIGAGYDNNWYQKPE 259
QY 174 KAPKLLIYDVNRPSPGIPDRFGSSGNTASLTITGAQAEADY--CSSFANSGLPG 231
Db 260 TAPKVLIIYNNRNPSPGIPDRFGSSGNTASLTITGAQAEADY--CSSFANSGLPG 319
QY 232 GGTKVTVL 239
Db 320 GGTKLTVL 327

RESULT 8
US-09-646-028-55
; Sequence 55, Application US/09646028
; Patent No. 6562347
; GENERAL INFORMATION:
; APPLICANT: Kwak, Larry
; APPLICANT: Biragyn, Arya
; TITLE OF INVENTION: METHODS AND COMPOSITIONS OF
; TITLE OF INVENTION: CHEMOKINE-TUMOR ANTIGEN FUSION PROTEINS AS CANCER VACCINES
; FILE REFERENCE: 14014.0316/P
; CURRENT APPLICATION NUMBER: US/09/646,028
; CURRENT FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 60/077,745
; PRIOR FILING DATE: 1998-03-12
; NUMBER OF SEQ ID NOS: 57
; SOFTWARE: FastSeq for Windows Version 3.0

; SEQ ID NO 55
; LENGTH: 339
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of artificial sequence./note=synthetic construct
US-09-646-028-55

Query Match 68.4%; Score 855.5; DB 4; Length 339;
Best Local Similarity 69.0%; Pred. No. 1.1e-56;
Matches 171; Conservative 29; Mismatches 39; Indels 9; Gaps 4;
QY 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSYSSMSVWRQAPGKLEWAVISYDGSNKYY 60
Db 85 EVQLLESGLVQSGGSLRLSCVASGLTFSSTAITWVRQAPGKLEWVSGISFGDTTYY 144
QY 61 ADSVKGRFTISRDNKNTLYLQNNLSLAEDTAVYYCARDR----YFDLWGRGTLTVSS- 115
Db 145 ADSVKGRFSASRDNSKNTVYLQNNLRPNDAVYFCANNTGNFCLDNWGQGLTVTVSSR 204
QY 116 GGGSGGGGGGG--GSQSALTQPSVSGSGSDTASLTISGLQAEADY--CSSFANSGLPG 173
Db 205 GGGSGGGGGGGSGGSGSVLTQPPSVSAAPGQRVTISCTGSRNIGAGYDNNWYQKPE 264
QY 174 KAPKLLIYDVNRPSPGIPDRFGSSGNTASLTITGAQAEADY--CSSFANSGLPG 231
Db 265 TAPKVLIIYNNRNPSPGIPDRFGSSGNTASLTITGAQAEADY--CSSFANSGLPG 324
QY 232 GGTKVTVL 239
Db 325 GGTKLTVL 332

RESULT 9
US-09-646-028-51
; Sequence 51, Application US/09646028
; Patent No. 6562347
; GENERAL INFORMATION:
; APPLICANT: Kwak, Larry
; APPLICANT: Biragyn, Arya
; TITLE OF INVENTION: METHODS AND COMPOSITIONS OF
; TITLE OF INVENTION: CHEMOKINE-TUMOR ANTIGEN FUSION PROTEINS AS CANCER VACCINES
; FILE REFERENCE: 14014.0316/P
; CURRENT APPLICATION NUMBER: US/09/646,028
; CURRENT FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 60/077,745
; PRIOR FILING DATE: 1998-03-12
; NUMBER OF SEQ ID NOS: 57
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 51
; LENGTH: 348
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of artificial sequence./note=synthetic construct
US-09-646-028-51

Query Match 68.4%; Score 855.5; DB 4; Length 348;
Best Local Similarity 69.0%; Pred. No. 1.1e-56;
Matches 171; Conservative 29; Mismatches 39; Indels 9; Gaps 4;
QY 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSYSSMSVWRQAPGKLEWAVISYDGSNKYY 60
Db 94 EVQLLESGLVQSGGSLRLSCVASGLTFSSTAITWVRQAPGKLEWVSGISFGDTTYY 153
QY 61 ADSVKGRFTISRDNKNTLYLQNNLSLAEDTAVYYCARDR----YFDLWGRGTLTVSS- 115
Db 154 ADSVKGRFSASRDNSKNTVYLQNNLRPNDAVYFCANNTGNFCLDNWGQGLTVTVSSR 213
QY 116 GGGSGGGGGGG--GSQSALTQPSVSGSGSDTASLTISGLQAEADY--CSSFANSGLPG 173
Db 214 GGGSGGGGGGGSGGSGSVLTQPPSVSAAPGQRVTISCTGSRNIGAGYDNNWYQKPE 273

QY 174 KAPKLLIYDVSNRPSGIGSNRPSGSGSDTASLTISGLQAEADYY--CSSFANSGLPFG 231
DB 274 TAPKVLIVSNRPSGVPDRPSGSGSGLTASLTISGLQAEADYY--CSSFANSGLPFG 333
QY 232 GGTKVTVL 239
DB 334 GGTKVTVL 341

RESULT 10

US-10-039-785-43
; Sequence 43, Application US/10039785
; Patent No. 6538938
; GENERAL INFORMATION:

; APPLICANT: Salcedo et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to TRAIL
; TITLE OF INVENTION: Receptors
; FILE REFERENCE: PF550

; CURRENT APPLICATION NUMBER: US/10/039,785

; CURRENT FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: 60/369,860
; PRIOR FILING DATE: 2002-04-05
; PRIOR APPLICATION NUMBER: 60/341,237
; PRIOR FILING DATE: 2001-12-20
; PRIOR APPLICATION NUMBER: 60/331,310
; PRIOR FILING DATE: 2001-11-14
; PRIOR APPLICATION NUMBER: 60/327,364
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/323,807
; PRIOR FILING DATE: 2001-09-21
; PRIOR APPLICATION NUMBER: 60/309,176
; PRIOR FILING DATE: 2001-08-02
; PRIOR APPLICATION NUMBER: 60/294,981
; PRIOR FILING DATE: 2001-06-04
; PRIOR APPLICATION NUMBER: 60/293,473
; PRIOR FILING DATE: 2001-05-25

; NUMBER OF SEQ ID NOS: 66

; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 43

; LENGTH: 245

; TYPE: PRT

; ORGANISM: Artificial sequence

; FEATURE:

; OTHER INFORMATION: T1014G03 scFv

US-10-039-785-43

Query Match 68.0%; Score 850.5; DB 4; Length 245;
Best Local Similarity 68.0%; Pred. No. 1.8e-56;
Matches 166; Conservative 30; Mismatches 43; Indels 5; Gaps 3;

QY 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSSYSMSWVRQAPGKGLEWVAIVSYDGSNKYY 60

DB 1 EVQLVQSGAEVMPGASVKLSKRVSGDITFTAYFIHWLRQAPGQGLEWMGNFNPISGTAGS 60

QY 61 ADSVKGRFTISRDNKNTLYLQMSLRADETAVYYCARD---RYFDLWGRGTLTVVSSGG 117

DB 61 AEKFRGRVAMTRDTISITAYMELNRLTDDTAVYYCARQHRGNTFDPWGQGTLLTVVSSGG 120

QY 118 GSGGGGGGGGGS-QSALTQPPASVSGSPQGSITISCTGTSSDIGAYNVSVYQYPGKAP 176

DB 121 GSGGGGGGGGGSQAQSALTQPPASVSGSPQGSITISCTGTSSDIGAYKXSVYQYHPGKAP 180

QY 177 KLLIYDVSNRPSGIGSNRPSGSGSDTASLTISGLQAEADYYCSSFANSGLPFG 235

DB 181 KLVIVSVNRPSSVSRPSGSGSDTASLTISGLQAEADYYCNSYQYNTWVFGGGTK 240

QY 236 VTVL 239

DB 241 VTVL 244

RESULT 11

US-10-039-785-47
; Sequence 47, Application US/10039785
; Patent No. 6538938

; GENERAL INFORMATION:

; APPLICANT: Salcedo et al.

; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to TRAIL

; TITLE OF INVENTION: Receptors

; FILE REFERENCE: PF550

; CURRENT APPLICATION NUMBER: US/10/039,785

; CURRENT FILING DATE: 2002-05-07

; PRIOR APPLICATION NUMBER: 60/369,860

; PRIOR FILING DATE: 2002-04-05

; PRIOR APPLICATION NUMBER: 60/341,237

; PRIOR FILING DATE: 2001-12-20

; PRIOR APPLICATION NUMBER: 60/331,310

; PRIOR FILING DATE: 2001-11-14

; PRIOR APPLICATION NUMBER: 60/331,044

; PRIOR FILING DATE: 2001-11-07

; PRIOR APPLICATION NUMBER: 60/327,364

; PRIOR FILING DATE: 2001-10-09

; PRIOR APPLICATION NUMBER: 60/323,807

; PRIOR FILING DATE: 2001-09-21

; PRIOR APPLICATION NUMBER: 60/309,176

; PRIOR FILING DATE: 2001-08-02

; PRIOR APPLICATION NUMBER: 60/294,981

; PRIOR FILING DATE: 2001-06-04

; PRIOR APPLICATION NUMBER: 60/293,473

; PRIOR FILING DATE: 2001-05-25

; NUMBER OF SEQ ID NOS: 66

; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 47

; LENGTH: 245

; TYPE: PRT

; ORGANISM: Artificial sequence

; FEATURE:

; OTHER INFORMATION: T1014B11 scFv

US-10-039-785-47

Query Match 67.2%; Score 839.5; DB 4; Length 245;
Best Local Similarity 65.2%; Pred. No. 1.2e-55;

Matches 159; Conservative 38; Mismatches 42; Indels 5; Gaps 3;

QY 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSSYSMSWVRQAPGKGLEWVAIVSYDGSNKYY 60

DB 1 EVQLVQSGAEVMPGASVKLSKRVSGDITFTAYFIHWLRQAPGQGLEWMGNFNPISGTAGS 60

QY 61 ADSVKGRFTISRDNKNTLYLQMSLRADETAVYYCARDY---FDLWGRGTLTVVSSGG 117

DB 61 PKFGRVAMTRDTISITAYMELNRLTASDITAYICARQHSNTFDPWGQGTLLTVVSSGG 120

QY 118 GSGGGGGGGGGS-QSALTQPPASVSGSPQGSITISCTGTSSDIGAYNVSVYQYPGKAP 176

DB 121 GSGGGGGGGGGSQAQSALTQPPASVSGSPQGSITISCTGTSDVGGYVSVYQYHPGKAP 180

QY 177 KLLIYDVSNRPSGIGSNRPSGSGSDTASLTISGLQAEADYYCSSFANSGLPFG 235

DB 181 KLVIVSVNRPSSVSRPSGSGSDTASLTISGLQAEADYYCNSYQYNTWVFGGGTK 240

QY 236 VTVL 239

DB 241 LTVL 244

RESULT 12

US-10-039-785-51
; Sequence 51, Application US/10039785
; Patent No. 6538938

; GENERAL INFORMATION:

; APPLICANT: Salcedo et al.

; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to TRAIL

; TITLE OF INVENTION: Receptors

; FILE REFERENCE: PF550

; CURRENT APPLICATION NUMBER: US/10/039,785
; CURRENT FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: 60/369,860
; PRIOR FILING DATE: 2002-04-05
; PRIOR APPLICATION NUMBER: 60/341,237
; PRIOR FILING DATE: 2001-12-20
; PRIOR APPLICATION NUMBER: 60/331,310
; PRIOR FILING DATE: 2001-11-14
; PRIOR APPLICATION NUMBER: 60/331,044
; PRIOR FILING DATE: 2001-11-07
; PRIOR APPLICATION NUMBER: 60/327,364
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/323,807
; PRIOR FILING DATE: 2001-09-21
; PRIOR APPLICATION NUMBER: 60/309,176
; PRIOR FILING DATE: 2001-08-02
; PRIOR APPLICATION NUMBER: 60/294,981
; PRIOR FILING DATE: 2001-06-04
; PRIOR APPLICATION NUMBER: 60/293,473
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 66
; SOFTWARE: Patent in Ver. 2.1
; SEQ ID NO 51
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: T1015A07 scfV
US-10-039-785-51

Query Match 67.2%; Score 839.5; DB 4; Length 245;
Best Local Similarity 65.1%; Pred. No. 1.2e-55;
Matches 162; Conservative 38; Mismatches 34; Indels 15; Gaps 5;
QY 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSYSSMSVWVQAQPGKLEWVAVI-----SYDG 55
Db 1 EVQLVQSGEGLVKPGGSLRLSCAASGFTFSYSSMSVWVQAQPGKLEWVAVI-----SYDG 55
QY 56 SNKYVADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVVYCARDY---FDLMGRGFLVT 112
Db 61 PKGFH-----GRVAMTRDTSISTAYMELTRLSADDTAIYVYCARQHHNSNTFDPWGQGLT 115
QY 113 VSSGGGGGGGGGGGGS-QSALTQPASVSGSPGSGITISCTGSSDYGAYNYVSWYQY 171
Db 116 VSSGGGGGGGGGGGGSQAQSLTQPASVSGSPGSGITISCTGSSDVGYNVSWYQY 175
QY 172 PGKAPKLLIYVSNRPSGISNRFSGSKSGDTSASLTISGLQAEDEADYVYCSFANSGLP-LF 230
Db 176 PGKAPKLLIYVSNRPSGISNRFSGSKSGDTSASLTISGLQAEDEADYVYCSFANSGLP-LF 235
QY 231 GGGTKVTVL 239
Db 236 GGGTKVTVL 244

RESULT 13
US-08-918-148-75
; Sequence 75, Application US/08918148A
; Patent No. 6342220
; GENERAL INFORMATION:
; APPLICANT: Adams, Camellia
; APPLICANT: W.
; APPLICANT: Carter, Paul J.
; APPLICANT: Fendly, Brian M.
; APPLICANT: Gurney, Austin L.
; TITLE OF INVENTION: Agonist Antibodies
; FILE REFERENCE: P0979
; CURRENT APPLICATION NUMBER: US/08/918,148A
; CURRENT FILING DATE: 1997-08-25
; NUMBER OF SEQ ID NOS: 79
; SEQ ID NO 75
; LENGTH: 245
; TYPE: PRT

; ORGANISM: artificial
US-08-918-148-75
Query Match 67.1%; Score 838.5; DB 4; Length 245;
Best Local Similarity 67.8%; Pred. No. 1.4e-55;
Matches 164; Conservative 27; Mismatches 44; Indels 7; Gaps 3;
QY 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSYSSMSVWVQAQPGKLEWVAVISYDGSNKYY 60
Db 3 EVQLVQSGGGLVKPGGSLRLSCAASGFTFSYSSMSVWVQAQPGKLEWVAVISYDGSNKYY 62
QY 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVVYCAR---DRYFDLMGRGTLVTYSSGG 117
Db 63 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVVYCARMSGEDAFDWGQGTMTYVSSGG 122
QY 118 GSGGGGGGGGGGQSALTQ-PASVSGSPGSGITISCTGSSDYGAYNYVSWYQYFGKAP 176
Db 123 GSGGGGGGGGGGSDIVMTQSPSTLSASVGDRAVLTCEASE---GIYHMLAWYQCKFGKAP 179
QY 177 KLLIYVSNRPSGISNRFSGSKSGDTSASLTISGLQAEDEADYVYCSFANSGLPFGGGTKV 236
Db 180 KLLIYKASSLASGAPSRFSGSGGADFTLTISLQPDDEFATYVYCCQYSNYPLTFGGGTKL 239
QY 237 TVL 238
Db 240 EV 241
RESULT 14
US-08-918-148-76
; Sequence 76, Application US/08918148A
; Patent No. 6342220
; GENERAL INFORMATION:
; APPLICANT: Adams, Camellia
; APPLICANT: W.
; APPLICANT: Carter, Paul J.
; APPLICANT: Fendly, Brian M.
; APPLICANT: Gurney, Austin L.
; TITLE OF INVENTION: Agonist Antibodies
; FILE REFERENCE: P0979
; CURRENT APPLICATION NUMBER: US/08/918,148A
; CURRENT FILING DATE: 1997-08-25
; NUMBER OF SEQ ID NOS: 79
; SEQ ID NO 76
; LENGTH: 245
; TYPE: PRT
; ORGANISM: artificial
US-08-918-148-76
Query Match 67.0%; Score 837.5; DB 4; Length 245;
Best Local Similarity 67.1%; Pred. No. 1.7e-55;
Matches 163; Conservative 28; Mismatches 45; Indels 7; Gaps 3;
QY 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSYSSMSVWVQAQPGKLEWVAVISYDGSNKYY 60
Db 3 EVQLVQSGGGLVKPGGSLRLSCAASGFTFSYSSMSVWVQAQPGKLEWVAVISYDGSNKYY 62
QY 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVVYCARDR---YFDLMGRGTLVTYSSGG 117
Db 63 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVVYCARDRSGSYGMDVWGRGTMTYVSSGG 122
QY 118 GSGGGGGGGGGGQSALTQ-PASVSGSPGSGITISCTGSSDYGAYNYVSWYQYFGKAP 176
Db 123 GSGGGGGGGGGGSDIQMTQSPSTLSASIGDRVITCEASE---GIYHMLAWYQCKFGKAP 179
QY 177 KLLIYVSNRPSGISNRFSGSKSGDTSASLTISGLQAEDEADYVYCSFANSGLPFGGGTKV 236
Db 180 KLLIYKASSLASGAPSRFSGSGGCTDFTLTISLQPDDEFATYVYCCQYSNYPLTFGGGTKL 239
QY 237 TVL 239
Db 240 EIL 242

RESULT 15

```

JS-08-918-148-78
; Sequence 78, Application US/08918148A
; Patent No. 6342220
; GENERAL INFORMATION:
; APPLICANT: Adams, Camellia
; APPLICANT: W.
; APPLICANT: Carter, Paul J.
; APPLICANT: Rendly, Brian M.
; APPLICANT: Gurney, Austin L.
; TITLE OF INVENTION: Agonist Antibodies
; FILE REFERENCE: P0979
; CURRENT APPLICATION NUMBER: US/08/918,148A
; CURRENT FILING DATE: 1997-08-25
; NUMBER OF SEQ ID NOS: 79
; SEQ ID NO 78
; LENGTH: 245
; TYPE: PRT
; ORGANISM: artificial
; FEATURE:
; NAME/KEY: unknown
; LOCATION: 208
; OTHER INFORMATION: unknown amino acid
US-08-918-148-78

```

```

Query Match      66.9%; Score 836.5; DB 4; Length 245;
Best Local Similarity 68.2%; Pred. No. 28-55;
Matches 165; Conservative 28; Mismatches 42; Indels 7; Gaps 3;

QY      1  QVQLQESGGGLVQPGGSLRLSCAASGFTFTSSYSSMSWVRQAPGKGLEWAVI SYDGSNKYY 60
      3  QVQLVESGGGLVQPGGSLRLSCAASGFTFSSHMNMWVRQAPGKGLEWSSYSSSSSYIYY 62
      61  ADSVKGKFTTIRSDNSKNTILYLNMSLRADETA VYICARDR---YFDLWGRGTLTVTSGG 117
      63  ADSVKGKFTTIRSDNAKNSLYLNMSLRADETA VYICARDRGSTGMDWNGRGLTVTVSSGG 122
      118  GSGGGSGGGGGGSGQSALTO-PASVSGSPGQSITISCTGTSIGAYNTVSVYQYQPKAP 176
      123  GSGGGSGGGGGGSKIQTQSPSTLSASIGDRVITTCRASE--GIYHFLAWYQKPKGKAP 179
      177  KLLIYDVSNRPSGIFSNRFSKSGDITASLTISGLQADEADYVYCCSFANSFGPLFGGGTKV 236
      180  KLLIYKASSLASGAPSRFSGSGGTPTFTYISSLQDPDFATYVYCOQYNYPILTFGGGTKL 239

      237  TV 238
      :
      240  EI 241
      Db

```

Search completed: March 15, 2004, 07:26:21
Job time : 23 secs

DM protein - protein search, using sw model

Run on: March 15, 2004, 07:25:43 ; Search time 20 Seconds

(without alignments)
119.489 Million cell updates/sec

Title: US-09-620-955B-6

Perfect score:

Sequence: 1 QVQLQESGGGLVQPGGSLRL.....CSSFANSGPLFGGGTKVTVL 239

Scoring table:

Gapop 10.0 , Gapext 0.5

Searched: 283366 seqs, 96191526 residues

Total number of hits satisfying chosen parameters:

Minimum DB sec length: 0

Minimum DB seq	length: 0
Maximum DB seq	length: 2000000000

2000 + 1000 = 3000
Minimum
Match

Post-processing: Minimum Match 0%
Maximum Match 100%

Maximum
Listing

[illegible]

Database : PIR 78:★

```
1:  pirl:*
```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query		DB	ID	Description
		Match	Length			
1	619	49.5	268	2	A56446	Ig heavy chain V r
2	589.5	47.2	249	2	S41374	single chain Fv an
3	549.5	44.0	140	2	S70442	Ig heavy chain pre
4	547	43.8	119	2	P36005	Ig heavy chain V r
5	546	43.7	121	2	G36005	Ig heavy chain V r
6	541	43.3	132	2	S11603	Ig heavy chain V r
7	540.5	43.2	233	2	JU5322	p53 specific singl
8	539.5	43.2	122	2	E36005	Ig heavy chain V r
9	539	43.1	134	2	S31679	Ig heavy chain V r
10	538	43.0	123	2	S38493	Ig heavy chain - h
11	537.5	43.0	114	2	S46391	Ig heavy chain V r
12	534.5	42.8	114	2	S46390	Ig heavy chain V r
13	534.5	42.8	118	2	S31116	Ig heavy chain - h
14	534.5	42.8	122	2	S31117	Ig heavy chain - h
15	533	42.6	111	2	PH1645	Ig heavy chain V r
16	533	42.6	121	2	S19666	Ig heavy chain V r
17	531.5	42.5	128	2	S48797	Ig heavy chain V r
18	531	42.5	133	2	A49038	Ig heavy chain V-I
19	529	42.3	135	2	S31598	Ig heavy chain V r
20	528	42.2	138	2	S31666	Ig heavy chain V r
21	526	42.1	130	2	S31601	Ig heavy chain V r
22	525.5	42.0	137	2	S31701	Ig heavy chain V r
23	521.5	41.7	139	2	S31674	Ig heavy chain V r
24	520.5	41.6	114	2	S46392	Ig heavy chain V r
25	520	41.6	119	2	S31107	Ig heavy chain - h
26	518.5	41.5	120	2	S31112	Ig heavy chain - h
27	518	41.4	119	2	S31108	Ig heavy chain - h
28	517.5	41.4	120	2	S48798	Ig heavy chain V r
29	517.5	41.4	147	2	I37780	Ig variable region

30	516	41.3	130	2	PL0098	IG heavy chain v r
31	516	41.3	140	2	S31588	IG heavy chain v r
32	515	41.2	119	2	D36005	IG heavy chain v r
33	512.5	41.0	128	2	S26790	IG heavy chain v r
34	511.5	40.9	141	2	S31669	IG heavy chain v r
35	511	40.9	119	2	C36005	IG heavy chain v r
36	509	40.7	109	2	PH1646	IG heavy chain v r
37	508.5	40.7	124	2	S20792	IG heavy chain v r
38	508	40.6	125	2	S30531	IG heavy chain v r
39	507.5	40.6	122	1	M3HJMM	IG heavy chain v l
40	505.5	40.4	133	2	S31510	IG heavy chain - h
41	505.5	40.4	136	2	S31587	IG heavy chain v r
42	505	40.4	111	2	PH1643	IG heavy chain - h
43	505	40.4	123	2	S31114	IG heavy chain - h
44	504.5	40.4	108	2	PH1642	IG heavy chain v r
45	503	40.2	117	2	S78486	IG heavy chain v r

ALIGNMENTS

```

RESULT 1
A56446
C: heavy chain V region (3H-3H scFv) - mouse (strain BALB/C)
C:Species: Mus musculus (house mouse)
C:CDate: 19-Jan-1996 #sequence_revision 19-Jan-1996 #text_change 16-Aug-1996
C:Accession: A56446
C:R: Tang, P.M.; Poltz, L.A.; Mahoney, W.C.; Schueler, P.A.
J. Biol. Chem. 270, 7829-7835, 1995
A:Title: A high affinity digoxin-binding protein displayed on M13 is functionally identical
A:Reference number: A56446, MUID:9222583; PMID:7713873
A:Accession: A56446
A:Status: Preliminary
A:Molecule type: mRNA
A:Residues: 1-268 <TAN>
A:Cross-references: GB:U20617
C:Keywords: heterotetramer; immunoglobulin

```

Query Match: 49.5%; Score 619; DB 2; Length 268;

Best Local Similarity 51.7%; Pred. No. 5.4e-36;
Matches 125; Conservative 34; Mismatches 75; Indels 8; Gaps 3;

[illegible]

RESULT 2

S41374
single chain Fv antibody - mouse
C:Species: Mus musculus (house mouse)
C:Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 06-Jan-1995
C:Accession: S41374
C:Author: R. Artsaenko, O.; Weiler, E.W.; Muentz, K.; Conrad, U.
C:Submitted to: the EMBL Data Library, January 1994
C:Description: Construction and functional characterization of a single chain Fv antibody
A:Reference number: S41374

A:Accession: S41374
A:Status: Preliminary
A:Molecule type: DNA
A:Residues: 1-249 <ART>
A:Cross-references: EMBL:Z29480

Query Match 47.2%; Score 589.5; DB 2; Length 249;
Best Local Similarity 51.4%; Pred. No. 5.5e-34;
Matches 125; Conservative 35; Mismatches 76; Indels 4;
Gaps 4;
QY 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSYSSMSWVRQAPGKLEWVAVISYDGSNKYY 60
DQ 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSYSSMSWVRQAPGKLEWVAVISYDGSNKYY 60
QY 61 ADSVKGRFTISRDNKNTLYLQNSLRADTAIVYCARDR---YFDLWGRGTLTVSS 116
DQ 61 VPRPQKAITATSTNTAYLLSSLTSDTAIVYCARDILYSLGWGSGTVTVSSR 120
QY 117 GGSQGGSGGGSGGSGGQALQTPASVSGSPQSGITTCGTSSDI--GAYNVVWYQYPG 173
DQ 121 GGSQGGSGGGSGGSGGSDTLTQSPFVVVIFGESVSLSCRSSKLLYSDGDSYLFWFLQRP 180
QY 174 KAPKLIYDVSNRPISGIRNFSGSKGDTASLTISGLQAEADYVCSFANSGLPFGG 233
DQ 181 QSPQLIYRMSNLASGVDPFRFGSGGTFTLRISREAVDGVYVCQHYEPLTFGAG 240
QY 234 TKV 236
DQ 241 TKL 243

RESULT 3
S70442
Ig heavy chain precursor V region (mu) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 24-Jul-1998 #sequence_revision 24-Jul-1998 #text_change 21-Jan-2000
C:Accession: S70442
R:Cuissinier, A.M.; Fumoux, F.; Fougereau, M.; Tonnelle, C.
Mol. Immunol. 29, 1363-1373, 1992
A:Title: IGM kappa/lambdA BBV human B cell clone: an early step of differentiation of f
A:Reference number: S70442; MUID:93024508; PMID:1383695
A:Accession: S70442
A:Status: not compared with conceptual translation
A:Molecule type: mRNA
A:Residues: 1-140 <CU>
C:Superfamily: immunoglobulin V region; immunoglobulin homology
F:34-117/Domain: immunoglobulin homology <IMM>

Query Match 44.0%; Score 549.5; DB 2; Length 140;
Best Local Similarity 87.6%; Pred. No. 1.8e-31;
Matches 106; Conservative 3; Mismatches 7; Indels 5; Gaps 1;
QY 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSYSSMSWVRQAPGKLEWVAVISYDGSNKYY 60
DQ 20 QVQLVESGGGVQPGGSLRLSCAASGFTFSYSSMSWVRQAPGKLEWVAVIRYDGSNKYY 79
QY 61 ADSVKGRFTISRDNKNTLYLQNSLRADTAIVYCARDR---YFDLWGRGTLTVSS 115
DQ 80 ADSVKGRFTISRDNKNTLYLQNSLRADTAIVYCARDHIVGATYFDYWGQGLTVTVSS 139
QY 116 G 116
DQ 140 G 140

RESULT 4
F36005
Ig heavy chain V region (M49) - human
C:Species: Homo sapiens (man)
C:Date: 21-Dec-1990 #sequence_revision 21-Dec-1990 #text_change 16-Dec-1998
C:Accession: F36005
R:Schroeder Jr., H.W.; Wang, J.Y.
Proc. Natl. Acad. Sci. U.S.A. 87, 6146-6150, 1990

A:Title: Preferential utilization of conserved immunoglobulin heavy chain variable gene
A:Reference number: A36005; MUID:90349571; PMID:2117273
A:Accession: F36005
A:Status: Preliminary
A:Molecule type: mRNA
A:Residues: 1-119 <SCH>
A:Cross-references: GB:M34026
C:Genetics:
A:Gens: GDB:IGH0; IGHDY1
A:Cross-references: GDB:118731; OMIM:146910
A:Map position: 14q32.33-14q32.33
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotrimer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 43.8%; Score 547; DB 2; Length 119;
Best Local Similarity 89.1%; Pred. No. 2.2e-31;
Matches 106; Conservative 5; Mismatches 4; Indels 4; Gaps 1;
QY 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSYSSMSWVRQAPGKLEWVAVISYDGSNKYY 60
DQ 1 QVQLVESGGGVQPGGSLRLSCAASGFTFSYSSMSWVRQAPGKLEWVAVISYDGSNKYY 60
QY 61 ADSVKGRFTISRDNKNTLYLQNSLRADTAIVYCARDR---YFDLWGRGTLTVSS 115
DQ 61 ADSVKGRFTISRDNKNTLYLQNSLRADTAIVYCARDKASDAFDYWGQGLTVTVSS 119

RESULT 5
G36005
Ig heavy chain V region (M74) - human
C:Species: Homo sapiens (man)
C:Date: 21-Dec-1990 #sequence_revision 21-Dec-1990 #text_change 16-Dec-1998
C:Accession: G36005
R:Schroeder Jr., H.W.; Wang, J.Y.
Proc. Natl. Acad. Sci. U.S.A. 87, 6146-6150, 1990
A:Title: Preferential utilization of conserved immunoglobulin heavy chain variable gene
A:Reference number: A36005; MUID:90349571; PMID:2117273
A:Accession: G36005
A:Status: Preliminary
A:Molecule type: mRNA
A:Residues: 1-121 <SCH>
A:Cross-references: GB:M34031
C:Genetics:
A:Gens: GDB:IGH0; IGHDY1
A:Cross-references: GDB:118731; OMIM:146910
A:Map position: 14q32.33-14q32.33
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotrimer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 43.7%; Score 546; DB 2; Length 121;
Best Local Similarity 86.4%; Pred. No. 2.7e-31;
Matches 107; Conservative 3; Mismatches 5; Indels 6; Gaps 1;
QY 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSYSSMSWVRQAPGKLEWVAVISYDGSNKYY 60
DQ 1 QVQLVESGGGVQPGGSLRLSCAASGFTFSYSSMSWVRQAPGKLEWVAVISYDGSNKYY 60
QY 61 ADSVKGRFTISRDNKNTLYLQNSLRADTAIVYCARDR---YFDLWGRGTLTVSS 114
DQ 61 ADSVKGRFTISRDNKNTLYLQNSLRADTAIVYCARDKDWGALFDYWGQGLTVTVSS 120
QY 115 S 115
DQ 121 S 121

RESULT 6
S31603
Ig heavy chain V region - human
C:Species: Homo sapiens (man)
C:Date: 03-Mar-1994 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999

Accession: S31603
 Cuisinier, A.M.; Gauthier, L.; Boubli, L.; Fougereau, M.; Tonnelie, C.
 Submitted to the EMBL Data Library, June 1992
 Description: Mechanisms that generate human immunoglobulin diversity operate from the
 Reference number: S31585
 Accession: S31603
 Status: preliminary
 Molecule type: mRNA
 Residues: 1-132 <CUI>
 Cross-references: GDB:118731; OMIM:146910
 Superfamily: immunoglobulin V region; immunoglobulin homology
 Keywords: heterotrimer; immunoglobulin
 F15-98/Domain: immunoglobulin homology <IMM>

Query Match 43.3%; Score 541; DB 2; Length 132;
 Best Local Similarity 89.7%; Pred. No. 6.5e-31;
 Matches 105; Conservative 3; Mismatches 7; Indels 2; Gaps 1;
 2Y 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSSYSMSWVRQAPGKLEWVAIVSYDGSNKYY 60
 16 QVQLVESGGGVQPGGSLRLSCAASGFTFSSYSMSWVRQAPGKLEWVAIVSYDGSNKYY 75
 2Y 61 ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYICARD--RYFDLWGRGTLTVSS 115
 2Y 76 ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYICARDLFFDYNGQGLTVTVSS 132

RESULT 7
 JC5322
 53 specific single-chain antibody Pab421 - human
 Species: Homo sapiens (man)
 Date: 15-May-1997 #sequence_revision 15-May-1997 #text_change 18-Jul-1997
 Accession: JC5322
 Jannot, C.B.; Hynes, N.E.
 Biochem. Biophys. Res. Commun. 230, 242-246, 1997
 Title: Characterization of scFv-421, a single-chain antibody targeted to p53.
 Reference number: JC5322; MUID:97168950; PMID:9016757
 Accession: JC5322
 Molecule type: mRNA
 Residues: 1-233 <JAN>
 Experimental source: hybridoma cell
 Comment: This protein specifically binds the tumor suppressor protein p53. It restores

Query Match 43.2%; Score 540.5; DB 2; Length 233;
 Best Local Similarity 49.2%; Pred. No. 1.3e-30;
 Matches 116; Conservative 31; Mismatches 84; Indels 5; Gaps 4;
 QY 5 QESGGGLVQPGGSLRLSCAASGFTFSSYSMSWVRQAPGKLEWVAIVSYDGSNKYYADSV 64
 Db 1 QESGAEVRSASVKLSCTTSFINDYIMHWKRPQGLEWIGRIDPENGADWTRSS 60
 QY 65 KCRFTISRDNSKNTLYLQMNSLRAEDTAVYICARDRYFDLWGRGTLTVSSGGGGGGGG 124
 Db 61 GVKATWTADTSNTAYLQSLTSDTAVYIC--NAGMDYWGQGTITVTVSSGGGGGGGGA 118
 QY 125 SGGGGSQALTO-PASVSGSPQQTITICTGSS-DICAVYVSWYQYQPKAPKLLIYD 182
 Db 119 SGGGGSDIELTQSPASLAVSLQQRATISCRASKSVSTSGYSYMEWNQKPKGPPRLIYL 178
 QY 183 VSNRSGISNRSKSGSDTASLTISGLQADEADYVCSFANSGLPFGGKTUTV 238
 Db 179 VSNLESGVPARESGSGSDTFLNIHPVEESDAATYTCQHIREL-TRSEGGTKLEI 233

RESULT 8
 E36005
 Ig heavy chain V region (W72) - human
 Species: Homo sapiens (man)
 Date: 21-Dec-1990 #sequence_revision 21-Dec-1990 #text_change 16-Dec-1998
 Accession: E36005
 Schroeder Jr., H.W.; Wang, J.Y.
 Proc. Natl. Acad. Sci. U.S.A. 87, 6146-6150, 1990
 Title: Preferential utilization of conserved immunoglobulin heavy chain variable gene

Reference number: A36005; MUID:90349571; PMID:2117273
 Accession: E36005
 Status: preliminary
 Molecule type: mRNA
 Residues: 1-122 <SCH>
 Cross-references: GDB:M34030
 Genes: GDB:IGHG; IGHDI1
 Cross-references: GDB:118731; OMIM:146910
 Map position: 14q32.33-14q32.33
 Superfamily: immunoglobulin V region; immunoglobulin homology
 Keywords: heterotrimer; immunoglobulin
 F15-98/Domain: immunoglobulin homology <IMM>

Query Match 43.2%; Score 539.5; DB 2; Length 122;
 Best Local Similarity 85.1%; Pred. No. 7.6e-31;
 Matches 105; Conservative 5; Mismatches 5; Indels 7; Gaps 1;
 QY 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSSYSMSWVRQAPGKLEWVAIVSYDGSNKYY 60
 Db 1 QVQLVESGGGVQPGGSLRLSCAASGFTFSSYSMSWVRQAPGKLEWVAIVSYDGSNKYY 60
 QY 61 ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYICARDY-----FDLWGRGTLTVV 113
 Db 61 ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYICARDHSSSWYGMVDVWGQGLTVTV 120
 QY 114 SS 115
 Db 121 SS 122

RESULT 9
 S31679
 Ig heavy chain V region - human (fragment)
 Species: Homo sapiens (man)
 Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
 Accession: S31679
 Cuisinier, A.M.; Gauthier, L.; Boubli, L.; Fougereau, M.; Tonnelie, C.
 Submitted to the EMBL Data Library, June 1992
 Description: Mechanisms that generate human immunoglobulin diversity operate from the
 Reference number: S31585
 Accession: S31679
 Status: preliminary
 Molecule type: mRNA
 Residues: 1-134 <CUI>
 Cross-references: EMBL:Z14203; NID:G30965; PIDN:CAA78572.1; PID:G30966
 Superfamily: immunoglobulin V region; immunoglobulin homology
 Keywords: heterotrimer; immunoglobulin
 F34-117/Domain: immunoglobulin homology <IMM>

Query Match 43.1%; Score 539; DB 2; Length 134;
 Best Local Similarity 90.4%; Pred. No. 9e-31;
 Matches 104; Conservative 4; Mismatches 7; Indels 0; Gaps 0;
 QY 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSSYSMSWVRQAPGKLEWVAIVSYDGSNKYY 60
 Db 20 QVQLVESGGGVQPGGSLRLSCAASGFTFSSYSMSWVRQAPGKLEWVAIVSYDGSNKYY 79
 QY 61 ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYICARDRYFDLWGRGTLTVSS 115
 Db 80 ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYICARESGDYWGQGLTVTVSS 134

RESULT 10
 S38493
 Ig heavy chain - human (fragment)
 Species: Homo sapiens (man)
 Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 23-Jul-1999
 Accession: S38493
 Marks, J.D.; Ouwehand, W.H.; Bye, J.M.; Finnern, R.; Gorick, B.D.; Voak, D.; Thorpe, S.
 Submitted to the EMBL Data Library, June 1993
 Description: Human antibody fragments specific for human blood group antigens from a p
 Reference number: S38488

A:Accession: S38493
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-123 <MAR>
A:Cross-references: EMBL:Z23036; NID:G414033; PIDN:CAA80571.1; PID:G414034
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 43.0%; Score 538; DB 2; Length 123;
Best Local Similarity 85.4%; Pred. No. 9.7e-31;
Matches 105; Conservative 4; Mismatches 6; Indels 8; Gaps 1;

QY 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSSYSMSWVRQAPGKLEWAVISYDGSNKYY 60
DB 1 QVQLQESGGGVQPGGSLRLSCAASGFTFSSYAMHWVRQAPGKLEWAVISYDGSNKYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQNSLRADTAIVYCARD-----YFDLWGRGTLVT 112
DB 61 ADSVKGRFTISRDNKNTLYLQNSLRADTAIVYCARDSSNNWYVYMDVWGKGTVT 120

QY 113 VSS 115
DB 121 VSS 123

RESULT 11
S46391
Ig heavy chain V region - human
C:Species: Homo sapiens (man)
C:Date: 27-Jan-1995 #sequence_revision 27-Jan-1995 #text_change 20-Jun-2000
C:Accession: S46391
R:Figini, M.; Marks, J.D.; Winter, G.; Griffiths, A.D.
J. Mol. Biol. 239, 68-78, 1994
A:Title: In vitro assembly of repertoires of antibody chains on the surface of phage by
A:Reference number: S46390; MUID:94254092; PMID:8196048
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-114 <FIG>
A:Cross-references: EMBL:Z31687; NID:G509784; PIDN:CAA83492.1; PID:G1335144
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 43.0%; Score 537.5; DB 2; Length 114;
Best Local Similarity 90.4%; Pred. No. 9.7e-31;
Matches 104; Conservative 5; Mismatches 5; Indels 1; Gaps 1;

QY 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSSYSMSWVRQAPGKLEWAVISYDGSNKYY 60
DB 1 QVNLRESGGGLVQPGGSLRLSCASGFTFSSYAMHWVRQAPGKLEWAVISYDGSNKYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQNSLRADTAIVYCARDYFDLWGRGTLVTSS 115
DB 61 ADSVKGRFTISRDNKNTLYLQNSLRADTAIVYCARD-FGDYWGQGLTIVTSS 114

RESULT 12
S46390
Ig heavy chain V region - human
C:Species: Homo sapiens (man)
C:Date: 27-Jan-1995 #sequence_revision 27-Jan-1995 #text_change 20-Jun-2000
C:Accession: S46390
R:Figini, M.; Marks, J.D.; Winter, G.; Griffiths, A.D.
J. Mol. Biol. 239, 68-78, 1994
A:Title: In vitro assembly of repertoires of antibody chains on the surface of phage by
A:Reference number: S46390; MUID:94254092; PMID:8196048
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-114 <FIG>
A:Cross-references: EMBL:Z31686; NID:G509782; PIDN:CAA83491.1; PID:G1335143

C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 42.8%; Score 534.5; DB 2; Length 114;
Best Local Similarity 90.4%; Pred. No. 1.6e-30;
Matches 104; Conservative 5; Mismatches 5; Indels 1; Gaps 1;

QY 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSSYSMSWVRQAPGKLEWAVISYDGSNKYY 60
DB 1 EVQLVESGGGVQPGGSLRLSCAASGFTFSSYAMHWVRQAPGKLEWAVISYDGSNKYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQNSLRADTAIVYCARDYFDLWGRGTLVTSS 115
DB 61 ADSVKGRFTISRDNKNTLYLQNSLRADTAIVYCARD-WGDYWGQGLTIVTSS 114

RESULT 13

S31116
Ig heavy chain - human
C:Species: Homo sapiens (man)
C:Date: 02-Dec-1993 #sequence_revision 26-May-1995 #text_change 17-Mar-1999
C:Accession: S31116
R:Raaphorst, F.M.; Timmers, B.; Kenter, M.J.H.; van Tol, M.J.D.; Vossen, J.M.; Schuurma
Eur. J. Immunol. 22, 247-251, 1992
A:Title: Restricted utilization of germ-line V(H)3 genes and short diverse third comple
A:Reference number: S31104; MUID:92111633; PMID:1730252
A:Accession: S31116
A:Status: preliminary; nucleic acid sequence not shown; translation not shown
A:Molecule type: mRNA
A:Residues: 1-118 <RAA>
A:Cross-references: EMBL:X62966
A:Note: the nucleotide sequence was submitted to the EMBL Data Library, October 1991
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 42.8%; Score 534.5; DB 2; Length 118;
Best Local Similarity 88.1%; Pred. No. 1.6e-30;
Matches 104; Conservative 4; Mismatches 7; Indels 3; Gaps 1;

QY 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSSYSMSWVRQAPGKLEWAVISYDGSNKYY 60
DB 1 QVQLVESGGGVQPGGSLRLSCAASGFTFSSYGMHWVRQAPGKLEWAVISYDGSNKYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQNSLRADTAIVYCARD--RYFDLWGRGTLVTSS 115
DB 61 ADSVKGRFTISRDNKNTLYLQNSLRADTAIVYCATDGGKAAPDYGQGTWTVSS 118

RESULT 14

S31117
Ig heavy chain - human
C:Species: Homo sapiens (man)
C:Date: 02-Dec-1993 #sequence_revision 26-May-1995 #text_change 17-Mar-1999
C:Accession: S31117
R:Raaphorst, F.M.; Timmers, B.; Kenter, M.J.H.; van Tol, M.J.D.; Vossen, J.M.; Schuurma
Eur. J. Immunol. 22, 247-251, 1992
A:Title: Restricted utilization of germ-line V(H)3 genes and short diverse third comple
A:Reference number: S31104; MUID:92111633; PMID:1730252
A:Accession: S31117
A:Status: preliminary; nucleic acid sequence not shown; translation not shown
A:Molecule type: mRNA
A:Residues: 1-122 <RAA>
A:Cross-references: EMBL:X62967
A:Note: the nucleotide sequence was submitted to the EMBL Data Library, October 1991
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 42.8%; Score 534.5; DB 2; Length 122;
Best Local Similarity 86.1%; Pred. No. 1.7e-30;
Matches 105; Conservative 3; Mismatches 7; Indels 7; Gaps 1;

QY 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSYSSMSWVROAPGKLEWVAIVSYDGSNKYY 60
 DB 1 QVQLVESGGGVQPGGSLRLSCAASGFTFSYSGHWVROAPGKLEWVAIVSYDGSNKYY 60
 QY 61 ADSVKGRFTISRDNKNTLYLQNSLRAEDTAVYYCARD-----RYFDLWGRGTLTV 113
 DB 61 ADSVKGRFTISRDNKNTLYLQNSLRAEDTAVYYCARDFFAPENWSHFYWGQGLTV 120
 QY 114 SS 115
 DB 121 SS 122

RESULT 15

PH1645
 Ig heavy chain V region (clone 6C8) - human (fragment)
 C/Species: Homo sapiens (man)
 C/Date: 24-Feb-1994 #sequence_revision 24-Feb-1994 #text_change 16-Aug-1996
 C/Accession: PH1645
 R/Hillson, J.L.; Karr, N.S.; Opplinger, I.R.; Mannik, M.; Sasso, E.H.
 J. Exp. Med. 178, 331-336, 1993
 A/Title: The structural basis of germline-encoded VH3 immunoglobulin binding to staphylococcal protein A
 A/Reference number: PH1645; MUID:93301610; PMID:8315388
 A/Accession: PH1645
 A/Molecule type: mRNA
 A/Residues: 1-111 <HIL>
 C/Superfamily: immunoglobulin V region; immunoglobulin homology
 C/Keywords: heterotetramer; immunoglobulin
 F/7-90/Domain: immunoglobulin homology <IMV>

Query Match 42.6%; Score 533; DB 2; Length 111;
 Best Local Similarity 92.8%; Pred. No. 1.9e-30;
 Matches 103; Conservative 2; Mismatches 2; Indels 4; Gaps 1;
 QY 9 GGLVQPGGSLRLSCAASGFTFSYSSMSWVROAPGKLEWVAIVSYDGSNKYYADSVKGRF 68
 DB 1 GGVLPGRSLRLSCAASGFTFSYSGHWVROAPGKLEWVAIVSYDGSNKYYADSVKGRF 60
 QY 69 TISRDNKNTLYLQNSLRAEDTAVYYCARD-----YFDLWGRGTLTVSS 115
 DB 61 TISRDNKNTLYLQNSLRAEDTAVYYCARDRGAWYFDLWGRGTLTVSS 111

Search completed: March 15, 2004, 07:28:22
 Job time : 21 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

M protein - protein search, using sw model

un on: March 15, 2004, 07:26:28 ; Search time 406 Seconds

(without alignments)

124,300 Million cell updates/sec

title: US-09-620-955B-6

erfect score: 1250

equences: 1 QVQLQESGGGLVQPGGSLRL.....CSSFANSGPLFGGCTKVTVL 239

coring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

searched: 809742 seqs, 211153259 residues

otal number of hits satisfying chosen parameters: 809742

inimum DB seq length: 0

aximum DB seq length: 2000000000

ost-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

atabase :

Published Applications AA:
1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
2: /cgn2_6/ptodata/1/pubpaa/FCI_NEW_PUB.pep.*
3: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep.*
5: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
6: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
7: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
8: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*
9: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*
10: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*
11: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*
12: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
13: /cgn2_6/ptodata/1/pubpaa/US10_PUBCOMB.pep.*
14: /cgn2_6/ptodata/1/pubpaa/US10_PUBCOMB.pep.*
15: /cgn2_6/ptodata/1/pubpaa/US10_PUBCOMB.pep.*
16: /cgn2_6/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
17: /cgn2_6/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
18: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1110	88.8	254	10	US-09-880-748-983
2	1106	88.5	256	10	US-09-880-748-839
3	1097	87.8	252	10	US-09-880-748-1627
4	1096	87.7	254	10	US-09-880-748-981
5	1095.5	87.6	241	10	US-09-880-748-2055
6	1093	87.4	252	10	US-09-880-748-956
7	1089.5	87.2	251	10	US-09-880-748-955
8	1089.5	87.2	251	10	US-09-880-748-1317
9	1088.5	87.1	251	10	US-09-880-748-1114
10	1084.5	86.8	253	10	US-09-880-748-1003
11	1082.5	86.6	251	10	US-09-880-748-1332
12	1079	86.3	254	10	US-09-880-748-1701
13	1079	86.3	254	10	US-09-880-748-1759
14	1078	86.2	256	10	US-09-880-748-1332
15	1077.5	86.2	253	10	US-09-880-748-989

254 10 US-09-880-748-881 Sequence 881, App
253 10 US-09-880-748-1007 Sequence 1007, App
244 10 US-09-880-748-1910 Sequence 1910, App
234 10 US-09-880-748-977 Sequence 977, App
240 10 US-09-880-748-2047 Sequence 2047, App
254 10 US-09-880-748-1428 Sequence 1428, App
253 10 US-09-880-748-1449 Sequence 1449, App
254 10 US-09-880-748-1075 Sequence 1075, App
254 10 US-09-880-748-1735 Sequence 1735, App
251 10 US-09-880-748-1605 Sequence 1605, App
253 10 US-09-880-748-1337 Sequence 1337, App
246 10 US-09-880-748-1314 Sequence 1314, App
254 10 US-09-880-748-1673 Sequence 1673, App
254 10 US-09-880-748-1898 Sequence 1898, App
240 10 US-09-880-748-1431 Sequence 1431, App
252 10 US-09-880-748-915 Sequence 915, App
247 10 US-09-880-748-1690 Sequence 1690, App
252 10 US-09-880-748-1634 Sequence 1634, App
240 10 US-09-880-748-1330 Sequence 1330, App
246 10 US-09-880-748-1324 Sequence 1324, App
250 10 US-09-880-748-883 Sequence 883, App
246 10 US-09-880-748-2077 Sequence 2077, App
243 10 US-09-880-748-995 Sequence 995, App
252 10 US-09-880-748-1634 Sequence 1634, App
248 10 US-09-880-748-1782 Sequence 1782, App
247 10 US-09-880-748-923 Sequence 923, App
247 14 US-10-322-673-48 Sequence 48, App1
248 10 US-09-880-748-1653 Sequence 1653, App
251 10 US-09-880-748-925 Sequence 925, App
255 10 US-09-880-748-1819 Sequence 1819, App
248 10 US-09-880-748-1404 Sequence 1404, App

ALIGNMENTS

RESULT 1
US-09-880-748-983
; Sequence 983, Application US/09880748
; Publication No. US2003005937A1

GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 983

LENGTH: 254

TYPE: PRT

ORGANISM: Homo sapiens

US-09-880-748-983

Query Match 88.8%; Score 1110; DB 10; Length 254;

Best Local Similarity 84.2%; Pred. No. 7.1e-73;
Matches 213; Conservative 14; Mismatches 12; Indels 14; Gaps 2;

QY 1 QVQLQESGGGLVQPGGSLRLCAASGFTFSYMSVQRQAPGKLEWVAIVSYDGSNKYY 60

Db 1 QVQLQESGGGVQPGSLRLCAASGFTFSYMSVQRQAPGKLEWVAIVSYDGSNKYY 60

QY 61 ADVKGRFTIRSDNSKNTLYLQMSLRADFTAVYYCARDR-----YFDLWGR 107
|||||

[illegible]

```

RESULT 2
US-09-880-748-839
; Sequence 839, Application US/09880748
; Publication No. US2003005937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PFS23
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 839
; LENGTH: 256
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-839

```

Query Match	88.54	Score	1106	DB	10	Length	256
Best Local Similarity	83.98	Pred. No.	1.4e-72				
Matches	213	Conservative	12	Mismatches	13	Indels	15
Gaps	2						
QY	2	VQLDSEGGGLVQPGGSLRLSCAASGFTFSSYSGMSWRQAPGKLEWVAIVSYDGNKKYYA	61				
DBb	2	VQLVQSGGGVLPQPGSLRLSCAASGFTFSSYSGMHWVRQAPGKLEWVAIVSYDGNKKYYA	61				
QY	62	DSVKGRTTISDNSKNLTLYQMNSLRADRTAVYVCADR-----YFDLWG	106				
DBb	62	DSVKGRTTISDNSKNLTLYQMNSLRADRTAVYVCADREAYVDILTGYLYYYVNDVWG	121				
QY	107	RGTLTVTVSSGGGGGGGGGGGSGQSALTPASVSGSPGQSIITISCTGTSSDIGAYNTVS	166				
DBb	122	RGTTTVTVSSGGGGGGGGGGGSGGQSQSVLTQPAVSGSPGQSIITISCTGTSSDVGGVNTVS	181				
QY	167	WYQYVPGKAPKLLIYDYSNPSGTSNEPFGSKSGDTSALTISGLQAEDEADYICSGSF-AN	225				
DBb	182	WYQHPGKAPKMLIYEGSKRFPSGVNRFPSGKSGNTASLTISGLQAEDEADYICSSYTTG	241				
QY	226	SGPLFGGCKVTVL	239				
DBb	242	STRVFGGCKLTVL	255				

RESULT 3
US-09-880-748-1627
; Sequence 1627, Application US/09880748
; Publication No. US2003005937A1
; GENERAL INFORMATION:

```

: APPLICANT: Ruben et al.
: TITLE OF INVENTION: Antibodies that Immunospecifically Bind Buys
: FILE REFERENCE: PF523
: CURRENT APPLICATION NUMBER: US/09/880,748
: CURRENT FILING DATE: 2001-06-15
: PRIOR APPLICATION NUMBER: 60/212,210
: PRIOR FILING DATE: 2000-06-15
: PRIOR APPLICATION NUMBER: 60/240,816
: PRIOR FILING DATE: 2000-10-17
: PRIOR APPLICATION NUMBER: 60/276,248
: PRIOR FILING DATE: 2001-03-16
: PRIOR APPLICATION NUMBER: 60/277,379
: PRIOR FILING DATE: 2001-03-21
: PRIOR APPLICATION NUMBER: 60/293,499
: PRIOR FILING DATE: 2001-05-25
: NUMBER OF SEQ ID NOS: 3239
: SOFTWARE: Patent In Ver. 2.0
: SEQ ID NO 1627
: LENGTH: 252
: TYPE: PRT
: ORGANISM: Homo sapiens
: US-09-880-748-1627

Query Match      87.8%   Score 1097;   DB 10;   Length 252;
Best Local Similarity 84.5%;   Pred. No. 6.1e-72;
Matches 212;   Conservative 12;   Mismatches 15;   Indels 12;   Gaps 2

QY      1  QVQLQESGGGLVQPGGSLRLSCAASGFTTSSYMSWVRQAPGKGLEWYAVISYDGSNKYY 60
Db      1  QVQLVQSGGGVQPGSLRLSCAASGFTTSSYGMHWVRQAPGKGLEWYAVISYDGSNKYY 60

QY      61  ADSVKGRFTISRDNKNTLYQMNSLRADFTAVYICARD-----RYFDLWGRGT 109
Db      61  ADSVKGRFTISRDNKNTLYQMNSLRADFTAVYICARSPGDDILTYGYKYFYDWGGQT 120

QY      110  LVTVSSGGGGSGGGGGGGSQSLAQPASVSGSPQSITISCTGTSDDIGAYNVVSWYQ 169
Db      121  LVTVSSGGGGSGGGGGGGSQSLVQPASVSGSPQSITISCTGTSDDVGVGYNVVSWYQ 180

QY      170  QYPKAPKLLIYDVSNRPSCIINRFGSGSGGTASLITISGLQAEADAYVCSFP-AKSGP 228
Db      181  QHPKAPKPLMIYSGSKRPISVNRFGSGSGGTASLITISGLQAEADAYVCSYTRSTR 240

QY      229  LFGGGTKVTVL 239
Db      241  VFGGGTKLTVL 251

```

RESULT 4
US-09-880-748-991
Sequence 981, Application US/09880748
Publication No. US2003005937A1
GENERAL INFORMATION:
APPLICANT: Ruben et al.
TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blyss
FILE REFERENCE: P9523
CURRENT APPLICATION NUMBER: US/09/880,748
CURRENT FILING DATE: 2001-06-15
PRIOR APPLICATION NUMBER: 60/212,210
PRIOR FILING DATE: 2000-06-15
PRIOR APPLICATION NUMBER: 60/240,816
PRIOR FILING DATE: 2000-10-17
PRIOR APPLICATION NUMBER: 60/276,248
PRIOR FILING DATE: 2001-03-16
PRIOR APPLICATION NUMBER: 60/277,379
PRIOR FILING DATE: 2001-03-21
PRIOR APPLICATION NUMBER: 60/293,499
PRIOR FILING DATE: 2001-05-25
NUMBER OF SEQ ID NOS: 3239
SOFTWARE: PatentIn ver. 2.0
SEQ ID NO 981
LENGTH: 254
TYPE: PRT

[illegible]

Query Match	87.4%;	Score	1093;	DB	10;	Length	252;	
Best Local Similarity	84.1%;	Prod. No.	1.2e-71;					
Matches	211;	Conservative	12;	Mismatches	16;	Indels	12;	
Gaps								
QY	1	QVQLQESGGGLVPGGSLRLS	CAASGFT	FSSYSMSW	RQAPGK	GLEWAV	SYDGSNKYY 60	
DB	1	QVQLVESGGGVQPGGSLRLS	CAASGFT	FSSYGMHW	RQAPGK	GLEWAV	SYDGSRDYY 60	
QY	61	ADSVKGRFTISRNSKNTLYL	QNNSLR	AEDTAVY	CARDR	-----	YFLDWRGRT 109	
DB	61	EDSVKGRFTISRNSKNTLYL	QNNSLR	AEDTAVY	CARDSGG	DLTGVMY	PFYDWGGRT 120	
QY	110	LVTVSSGGSGGGGGGGGSG	QSALTP	ASVSGSP	QGQISIT	CTGTS	SDIGAYNVSWYQ 169	
DB	121	TVTVSSGGSGGGGGGGGSG	QSALTP	ASVSGSP	QGQISIT	CTGTS	SDVGGXNVSWYQ 180	
QY	170	QYPCAKPLLIYDVSNRP	SGISNRP	FGSKSG	GTASLT	ISGLQAE	ADAYGSSP-ANSGP 228	
DB	181	QHPGKAPKLMIFYGSR	RRPSCV	SNRFSG	SKSGNT	ASLTISG	PGQAEADYYC	SSYTTTRSTR 240
QY	229	LFGGGT	KVTVL	239				
DB	241	VFGG	GT	KLTVL	251			

```

RESULT 7
US-09-880-748-955
; Sequence 955, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunosppecifically Bind BlyS
; FILE REFERENCE: P523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,916
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16

```

```

1. ORGANISM: Homo sapiens
JS-09-880-748-981

Query Match      87.7%; Score 1096; DB 10; Length 254;
Best Local Similarity 84.2%; Pred. No. 7.3e-72;
Matches 213; Conservative 13; Mismatches 13; Indels 14; Gaps 3

2y 1 QVQIQESGGGLVQGGSLRLSCAASGFTFSYSMNWVRQAPGKLEWVAIVSYDGSNKYY 60
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
db 1 QVQLVQSGGGVYVQGRSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

2y 61 ADSVKGRFTISRDN SKNTLYIQMNSLRABDTAVYYCARDR -YFDL-----WGR 107
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
db 61 ADSVKGRFTISRDN SKNTLYIQMNSLRAGDTAVYYCARDRGYYDILTYRGHGMDVGR 120
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

2y 108 GTLVTVSGGGGGGGGGGGGGGSGSALQTQPSVSGSPGQSITICTGTGSDDTGAYNYSW 167
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
db 121 GTLVTVSGGGGGGGGGGGGGGSGSVLTQPSVSGSPGQSITICTGTGSDVGGNYYSW 180
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

2y 168 YQQYPGKAPKLLIYDVNRPSGIGTSNRFSGSKSGDTSALTSISGQAEDADYCCSF -ANS 226
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
db 181 YQQHFGKAPKLMIVEGSKRPSGVNRRPSGSKSGNTASLTISGLQADEADYCCSSYTRS 240
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

2y 227 GLPFGGGTKVTVL 239
   : ||||| : ||
db 241 TRVFGGGTKVTVL 253
   : ||||| : ||

```

```

RESULT 5
US-09-880-748-2055
; Sequence 2055, Application US/09880748
; Publication No. US2003005937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2055
; LENGTH: 241
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-2055

```

Query Match	87.6%;	Score 1095.5;	DB 10;	Length 241;
Best Local Similarity	86.2%;	Pred. No. 7.5e-72;		
Matches 207;	Conservative 16;	Mismatches 16;	Indels 1;	Gaps 1;
QY	1	QVQLQESGGGLVQPGGSLRLSCAASGFTFSYSSMSVVRQAPGKLEWAVISYDSGNKYY	60	
Ddb	1	QVQLVQSGEDVVQPSRLSLSCAASGFTISYAHMWVRQAPGKLEWAVISYDSGNKYY	60	
QY	61	ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYICARDRYFDLWGRTGLVTVSSGGGGS	120	
Ddb	61	ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYICARDLDPDYWGQGLTVTVSSGGGGS	120	
QY	121	GGGSGGGGSSQSLTPAPASVSGSPGQITISCTGTSSDICAIVYVSWYQYQPKAPKLLI	180	
Ddb	121	GGGSGGGGGSVLTPPPASGSPGQVITISCTGTSSDVGVYVSWYQQHFGKAPKFI	180	
QY	181	VDVSNRPSGGINRPSGSKSGDPTASITSLGIQARDADYVYCSSEAN-SGPIFGGGTKVTVI	239	

PRIOR APPLICATION NUMBER: 60/277,379
PRIOR FILING DATE: 2001-03-21
PRIOR APPLICATION NUMBER: 60/293,499
PRIOR FILING DATE: 2001-05-25
NUMBER OF SEQ ID NOS: 3239
SOFTWARE: Patent In Ver. 2.0
SEQ ID NO 955
LENGTH: 251
TYPE: PRT
ORGANISM: Homo sapiens
US-09-880-748-955

Query Match 87.2%; Score 1089.5; DB 10; Length 251;
Best Local Similarity 83.6%; Pred. No. 2.1e-71;
Matches 209; Conservative 14; Mismatches 16; Indels 11; Gaps 2;

QY 1 QVQLQESGGGLVQPGGSLRLCAASGFTFSYSSMSWVRQAPGKLEWVAIVSYDGSNKYY 60
DB 1 EVQLVESGGGVQPGGSLRLCAASGFTFSYSGHHWVRQAPGKLEWVAIVSYDGSNKYY 60
QY 61 ADSVKGRFTISRDNKNTLYLQMSLRADTAIVYCARSHYDILTLGLNYYWYFDLWGRGTL 110
DB 61 ADSVKGRFTISRDNKNTLYLQMSLRADTAIVYCARSHYDILTLGLNYYWYFDLWGRGTM 120
QY 111 VTVSSGGGGSGGGGSGGSSQSLTQPASVSGSPGQSIITISCTGSSDIDGAYNVYSWYQQ 170
DB 121 VTVSSGGGGSGGGGSGGSSQSLTQPASVSGSPGQSIITISCTGSSDIDGAYNVYSWYQQ 180
QY 171 YPGKAPKLLIYDVSNRPSGISNRPSGSKSGDTSALTISGLQAEDEADYYCSSF-ANSGPL 229
DB 181 HPKAPKLLIYEGSKRPSPGVSNRPSGSKSGNTASLTISGLQAEDEADYYCSTYTRSTRV 240
QY 230 FGGGKTVTL 239
DB 241 FGGGKTLTVL 250

RESULT 8

US-09-880-748-1317
Sequence 1317, Application US/09880748
Publication No. US20030059937A1
GENERAL INFORMATION:
APPLICANT: Ruben et al.
TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
FILE REFERENCE: P2523
CURRENT APPLICATION NUMBER: US/09/880,748
CURRENT FILING DATE: 2001-06-15
PRIOR APPLICATION NUMBER: 60/212,210
PRIOR FILING DATE: 2000-06-15
PRIOR APPLICATION NUMBER: 60/240,816
PRIOR FILING DATE: 2000-10-17
PRIOR APPLICATION NUMBER: 60/276,248
PRIOR FILING DATE: 2001-03-16
PRIOR APPLICATION NUMBER: 60/277,379
PRIOR FILING DATE: 2001-03-21
PRIOR APPLICATION NUMBER: 60/293,499
NUMBER OF SEQ ID NOS: 3239
SOFTWARE: Patent In Ver. 2.0
SEQ ID NO 1317
LENGTH: 251
TYPE: PRT
ORGANISM: Homo sapiens
US-09-880-748-1317

Query Match 87.2%; Score 1089.5; DB 10; Length 251;
Best Local Similarity 83.6%; Pred. No. 2.1e-71;
Matches 209; Conservative 14; Mismatches 16; Indels 11; Gaps 2;

QY 1 QVQLQESGGGLVQPGGSLRLCAASGFTFSYSSMSWVRQAPGKLEWVAIVSYDGSNKYY 60
DB 1 QITLQESGGGVQPGGSLRLCAASGFTFSYSGHHWVRQAPGKLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQMSLRADTAIVYCARSHYDILTLGLNYYWYFDLWGRGTL 110
DB 61 ADSVKGRFTISRDNKNTLYLQMSLRADTAIVYCARSHYDILTLGLNYYWYFDLWGRGTL 120
QY 111 VTVSSGGGGSGGGGSGGSSQSLTQPASVSGSPGQSIITISCTGSSDIDGAYNVYSWYQQ 170
DB 121 VTVSSGGGGSGGGGSGGSSQSLTQPASVSGSPGQSIITISCTGSSDIDGAYNVYSWYQQ 180
QY 171 YPGKAPKLLIYDVSNRPSGISNRPSGSKSGDTSALTISGLQAEDEADYYCSSF-ANSGPL 229
DB 181 HPKAPKLLIYEGSKRPSPGVSNRPSGSKSGNTASLTISGLQAEDEADYYCSTYTRSTRV 240
QY 230 FGGGKTVTL 239
DB 241 FGGGKTLTVL 250

RESULT 9

US-09-880-748-1114
Sequence 1114, Application US/09880748
Publication No. US20030059937A1
GENERAL INFORMATION:
APPLICANT: Ruben et al.
TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
FILE REFERENCE: P2523
CURRENT APPLICATION NUMBER: US/09/880,748
CURRENT FILING DATE: 2001-06-15
PRIOR APPLICATION NUMBER: 60/212,210
PRIOR FILING DATE: 2000-06-15
PRIOR APPLICATION NUMBER: 60/240,816
PRIOR FILING DATE: 2000-10-17
PRIOR APPLICATION NUMBER: 60/276,248
PRIOR FILING DATE: 2001-03-16
PRIOR APPLICATION NUMBER: 60/277,379
PRIOR FILING DATE: 2001-03-21
PRIOR APPLICATION NUMBER: 60/293,499
NUMBER OF SEQ ID NOS: 3239
SOFTWARE: Patent In Ver. 2.0
SEQ ID NO 1114
LENGTH: 251
TYPE: PRT
ORGANISM: Homo sapiens
US-09-880-748-1114

Query Match 87.1%; Score 1088.5; DB 10; Length 251;
Best Local Similarity 83.2%; Pred. No. 2.5e-71;
Matches 208; Conservative 16; Mismatches 15; Indels 11; Gaps 2;

QY 1 QVQLQESGGGLVQPGGSLRLCAASGFTFSYSSMSWVRQAPGKLEWVAIVSYDGSNKYY 60
DB 1 EVQLVESGGGVQPGGSLRLCAASGFTVNSYAMHWVRQAPGKLEWVAIVSYDGSNKYY 60
QY 61 ADSVKGRFTISRDNKNTLYLQMSLRADTAIVYCARSHYDILTLGLNYYWYFDLWGRGTL 110
DB 61 ADSVKGRFTISRDNKNTLYLQMSLRADTAIVYCARSHYDILTLGLNYYWYFDLWGRGTT 120
QY 111 VTVSSGGGGSGGGGSGGSSQSLTQPASVSGSPGQSIITISCTGSSDIDGAYNVYSWYQQ 170
DB 121 VTVSSGGGGSGGGGSGGSSQSLTQPASVSGSPGQSIITISCTGSSDIDGAYNVYSWYQQ 180
QY 171 YPGKAPKLLIYDVSNRPSGISNRPSGSKSGDTSALTISGLQAEDEADYYCSSF-ANSGPL 229
DB 181 HPKAPKLLIYEGSKRPSPGVSNRPSGSKSGNTASLTISGLQAEDEADYYCSTYTRSTRV 240
QY 230 FGGGKTVTL 239
DB 241 FGGGKTLTVL 250

RESULT 10

US-09-880-748-1003
Sequence 1003, Application US/09880748

QY 168 YQYFGKAPKLLIYDVSNRPSGNSRFGSGKSGDTASLTISGLQAEADYDCCSSP-ANS 226
 Db 181 YQYFGKAPKLLIYDVSNRPSGNSRFGSGKSGNTASLTISGLQAEADYDCCSSYTTTS 240
 QY 227 GFLFGGKTKTVL 239
 Db 241 TRVFGGKTKTVL 253

RESULT 13
 US-09-880-748-1759
 ; Sequence 1759, Application US/09880748
 ; Publication No. US2003005937A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ruben et al.
 ; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
 ; FILE REFERENCE: PF523
 ; CURRENT APPLICATION NUMBER: US/09/880,748
 ; CURRENT FILING DATE: 2001-06-15
 ; PRIOR APPLICATION NUMBER: 60/212,210
 ; PRIOR FILING DATE: 2000-06-15
 ; PRIOR APPLICATION NUMBER: 60/240,816
 ; PRIOR FILING DATE: 2000-10-17
 ; PRIOR APPLICATION NUMBER: 60/276,248
 ; PRIOR FILING DATE: 2001-03-16
 ; PRIOR APPLICATION NUMBER: 60/277,379
 ; PRIOR FILING DATE: 2001-03-21
 ; PRIOR APPLICATION NUMBER: 60/293,499
 ; PRIOR FILING DATE: 2001-05-25
 ; NUMBER OF SEQ ID NOS: 3239
 ; SOFTWARE: PatentIn Ver. 2.0
 ; SEQ ID NO 1759
 ; LENGTH: 254
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 ; US-09-880-748-1759

Query Match 86.3%; Score 1079; DB 10; Length 254;
 Best Local Similarity 82.2%; Pred. No. 1.2e-70;
 Matches 208; Conservative 16; Mismatches 15; Indels 14; Gaps 2;

QY 1 QVLOESGGGLVQPGSLRLSCAASGFTFSYMSWVRQAPGKLEWVAIVSYDGSNKYY 60
 Db 1 QVQLVQSGGVLVQPGSLRLSCAASGFTFSYGHVWRQAPGKLEWVAIVSYDGSIRKY 60
 QY 61 ADSVKGRTTISRDNKNTLYLQMSLRADTAIVYCARDRYFDL-----WGR 107
 Db 61 ADSVGRFTISRDNKNTLYLQMSLRADTAIVYCARSGYDILTYGYVGVGRMDVWGR 120
 QY 108 GTLVTVSSGGGGGGGGGGGSGSALTQPASVSGSPGQITISCTGTSSDYGAYVYVSW 167
 Db 121 GTMTVTVSSGGGGGGGGGGGSGSALTQPASVSGSPGQITISCTGTSSDVGGINVYVSW 180
 QY 168 YQYFGKAPKLLIYDVSNRPSGNSRFGSGKSGDTASLTISGLQAEADYDCCSSP-ANS 226
 Db 181 YQYFGKAPKLLIYDVSNRPSGNSRFGSGKSGNTASLTISGLQAEADYDCCSSYTTTS 240
 QY 227 GFLFGGKTKTVL 239
 Db 241 TRVFGGKTKTVL 253

RESULT 14
 US-09-880-748-1392
 ; Sequence 1392, Application US/09880748
 ; Publication No. US2003005937A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ruben et al.
 ; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
 ; FILE REFERENCE: PF523
 ; CURRENT APPLICATION NUMBER: US/09/880,748
 ; CURRENT FILING DATE: 2001-06-15

; PRIOR APPLICATION NUMBER: 60/212,210
 ; PRIOR FILING DATE: 2000-06-15
 ; PRIOR APPLICATION NUMBER: 60/240,816
 ; PRIOR FILING DATE: 2000-10-17
 ; PRIOR APPLICATION NUMBER: 60/276,248
 ; PRIOR FILING DATE: 2001-03-16
 ; PRIOR APPLICATION NUMBER: 60/277,379
 ; PRIOR FILING DATE: 2001-03-21
 ; PRIOR APPLICATION NUMBER: 60/293,499
 ; PRIOR FILING DATE: 2001-05-25
 ; NUMBER OF SEQ ID NOS: 3239
 ; SOFTWARE: PatentIn Ver. 2.0
 ; SEQ ID NO 1392
 ; LENGTH: 256
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 ; US-09-880-748-1392

Query Match 86.2%; Score 1078; DB 10; Length 256;
 Best Local Similarity 81.2%; Pred. No. 1.5e-70;
 Matches 207; Conservative 18; Mismatches 14; Indels 16; Gaps 2;

QY 1 QVLOESGGGLVQPGSLRLSCAASGFTFSYMSWVRQAPGKLEWVAIVSYDGSNKYY 60
 Db 1 QVQLVQSGGVLVQPGSLRLSCAASGFTFSNDMSWVRQAPGKLEWVSGISGSGSKYY 60
 QY 61 ADSVKGRTTISRDNKNTLYLQMSLRADTAIVYCARDRY-----FDLW 105
 Db 61 ADSVKGRTTISRDNKNTLYLQMSLRADTAIVYCARDRYDILTYGYVPGLDADFDW 120
 QY 106 GRGTLTVTVSSGGGGGGGGGGGSGSALTQPASVSGSPGQITISCTGTSSDYGAYVYV 165
 Db 121 QGTLTVTVSSGGGGGGGGGGGSGSALTQPASVSGSPGQITISCTGTSSDVGGINVYV 180
 QY 166 SWYQYFGKAPKLLIYDVSNRPSGNSRFGSGKSGDTASLTISGLQAEADYDCCSSP-A 224
 Db 181 SWYQYFGKAPKLLIYDVSNRPSGNSRFGSGKSGNTASLTISGLQAEADYDCCSYTT 240
 QY 225 NSGFLFGGKTKTVL 239
 Db 241 RSTRVFGGKTKTVL 255

RESULT 15
 US-09-880-748-989
 ; Sequence 989, Application US/09880748
 ; Publication No. US2003005937A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ruben et al.
 ; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
 ; FILE REFERENCE: PF523
 ; CURRENT APPLICATION NUMBER: US/09/880,748
 ; CURRENT FILING DATE: 2001-06-15
 ; PRIOR APPLICATION NUMBER: 60/212,210
 ; PRIOR FILING DATE: 2000-06-15
 ; PRIOR APPLICATION NUMBER: 60/240,816
 ; PRIOR FILING DATE: 2000-10-17
 ; PRIOR APPLICATION NUMBER: 60/276,248
 ; PRIOR FILING DATE: 2001-03-16
 ; PRIOR APPLICATION NUMBER: 60/277,379
 ; PRIOR FILING DATE: 2001-03-21
 ; PRIOR APPLICATION NUMBER: 60/293,499
 ; PRIOR FILING DATE: 2001-05-25
 ; NUMBER OF SEQ ID NOS: 3239
 ; SOFTWARE: PatentIn Ver. 2.0
 ; SEQ ID NO 989
 ; LENGTH: 253
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 ; US-09-880-748-989

Query Match 86.2%; Score 1077.5; DB 10; Length 253;
 Best Local Similarity 83.3%; Pred. No. 1.6e-70;

Matches 210;		Conservative	14;	Mismatches	15;	Indels	13;	Gaps	3;
NY	1	QVQLAESGGGLVQPGGSLRLSCAASGFTFSSYSMSWVRQAPGKGLEWVAVISYDGSNKYY	60						
ib	1	QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYANGVRQAPGKGLEWVAVISYDGSNKYY	60						
NY	61	ADSVKGRFTISRDNSKNTLYLQWNSLRADDTAVYICARDR-----YF---DLWGRG	108						
ib	61	ADSVKGRFTISRDNSKNTLYLQWNSLRADDTAVYICARDR-----YF---DLWGRG	120						
NY	109	TLVTSSGGGSGGGSGGSGSALTQPASVSGSPGQSITISCTGTSDDIGAYNVVSWY	168						
ib	121	TLVTSSGGGSGGGSGGSGSGLTQPASVSGSPGQSITISCTGTSDDIGAYNVVSWY	180						
NY	169	QQYPGKAPKLLIYDVSNRPISGNSRPSGSKSGDTASLTISGLQADEADYYCSSF-ANSG	227						
ib	181	QQHPGKAPKLLIYDVSNRPISGNSRPSGSKSGDTASLTISGLQADEADYYCSSYTRST	240						
NY	228	PLFGGKTVTVL	239						
ib	241	RVFPGGKTVTVL	252						

Search completed: March 15, 2004, 07:36:34
Job time : 407 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

M protein - protein search, using sw model

run on: March 15, 2004, 07:25:43 ; Search time 45 Seconds

(without alignments)
1675.752 Million cell updates/sec

Title: US-09-620-955b-6

Perfect score: 1250
Sequence: 1 QVQLQESGGGLVQPGGSLRL.....CSSFANGSGPLFGGCTKVTVL 239

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1017041 seqs, 315518202 residues

Total number of hits satisfying chosen parameters: 1017041

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

SPREMBL.25.*

1: sp_archaea.*

2: sp_bacteria.*

3: sp_fungi.*

4: sp_human.*

5: sp_invertebrate.*

6: sp_mammal.*

7: sp_mhc.*

8: sp_organelle.*

9: sp_phage.*

10: sp_plant.*

11: sp_rhod.*

12: sp_virus.*

13: sp_vertebrate.*

14: sp_unclassified.*

15: sp_virus.*

16: sp_bacteriaph.*

17: sp_archaeap.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	735.5	58.8	298	11 Q9QYF0	Q9QYF0 mus musculus
2	621	49.7	241	11 Q921A6	Q921A6 mus musculus
3	600	48.0	243	11 Q7TQM2	Q7TQM2 mus musculus
4	552.5	44.2	613	4 Q8WUK1	Q8WUK1 homo sapien
5	524	41.9	113	4 Q9UL90	Q9UL90 homo sapien
6	517.5	41.4	218	11 Q925S1	Q925S1 mus musculus
7	509	40.7	116	4 Q9UL93	Q9UL93 homo sapien
8	501	40.1	597	4 Q96BB9	Q96BB9 homo sapien
9	494	39.5	147	4 Q9Y509	Q9Y509 homo sapien
10	489.5	39.2	122	4 Q9UL84	Q9UL84 homo sapien
11	487	39.0	121	4 Q9UL71	Q9UL71 homo sapien
12	485.5	38.8	479	11 Q91WP5	Q91WP5 mus musculus
13	484.5	38.8	114	4 Q9UL91	Q9UL91 homo sapien
14	482.5	38.6	118	4 Q9UL72	Q9UL72 homo sapien
15	471	37.7	487	11 Q95K44	Q95K44 mus musculus
16	465.5	37.2	112	4 Q9HCC1	Q9HCC1 homo sapien

17	465.5	37.2	493	4 Q8NCL6	Q8NCL6 homo sapien
18	459.5	36.8	473	11 Q91205	Q91205 mus musculus
19	458.5	36.7	499	4 Q8NSK4	Q8NSK4 homo sapien
20	457	36.6	494	4 Q96K68	Q96K68 homo sapien
21	456.5	36.5	487	11 Q80217	Q80217 mus musculus
22	450	36.0	95	4 Q9UL86	Q9UL86 homo sapien
23	450	36.0	119	11 Q920E7	Q920E7 mus musculus
24	450	36.0	573	4 Q8WU38	Q8WU38 homo sapien
25	441.5	35.3	482	4 Q7Z351	Q7Z351 homo sapien
26	440.5	35.2	486	11 Q91207	Q91207 mus musculus
27	438.5	35.1	480	11 Q91XE1	Q91XE1 mus musculus
28	437.5	35.0	470	4 Q7Z5W1	Q7Z5W1 homo sapien
29	426.5	34.1	437	11 Q9RIA4	Q9RIA4 mus musculus
30	425.5	34.0	469	11 Q8RV99	Q8RV99 mus musculus
31	423	33.8	484	11 Q8VEA0	Q8VEA0 mus musculus
32	416.5	33.3	521	4 Q8N4Y9	Q8N4Y9 homo sapien
33	413	33.0	131	4 Q9UL88	Q9UL88 homo sapien
34	403	32.2	479	11 Q7TMM4	Q7TMM4 mus musculus
35	398.5	31.9	237	4 Q8WTU6	Q8WTU6 homo sapien
36	397.5	31.8	237	4 Q8WUK4	Q8WUK4 homo sapien
37	394	31.5	236	4 Q96E61	Q96E61 homo sapien
38	388.5	31.1	170	11 Q925S2	Q925S2 mus musculus
39	379.5	30.4	124	6 Q9N0W6	Q9N0W6 oryctolagus
40	377.5	30.2	124	6 Q9N0W4	Q9N0W4 oryctolagus
41	376	30.1	236	4 Q8NEJ1	Q8NEJ1 homo sapien
42	375.5	30.0	110	4 Q8TE63	Q8TE63 homo sapien
43	373	29.8	104	4 Q9UL87	Q9UL87 homo sapien
44	370.5	29.6	124	4 Q9UL92	Q9UL92 homo sapien
45	367.5	29.4	484	11 Q99LA6	Q99LA6 mus musculus

ALIGNMENTS

RESULT 1
Q9QYF0 PRELIMINARY, PRT; 298 AA.
ID Q9QYF0
AC Q9QYF0
DT 01-MAY-2000 (TRENBLrel. 13, Created)
DT 01-MAY-2000 (TRENBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TRENBLrel. 25, Last annotation update)
DE CN 8 scfv.
GN CN 8.

OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;

RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Balb/c; TISSUE=Spleen;
RX MEDLINE=20183931; PubMed=10706631;
RA Shiohara N., Demura T., Fukuda H.;
RT "Isolation of a vascular cell wall-specific monoclonal antibody
RT recognizing a cell polarity by using a phase display subtraction
RT method.";

RL Proc. Natl. Acad. Sci. U.S.A. 97:2585-2590(2000).

DR EMBL; AB036341; BAA88633.1; -

DR PIR; A33933; A33933.

DR PIR; S19112; S19112.

DR HSSP; P01607; 1REI.

DR InterPro; IPR007110; IG-like.

DR InterPro; IPR003596; IG_v.

DR Pfam; PF00047; Ig_2.

DR SMART; SM00406; Igv; 2.

DR PROSITE; PS50835; IG_LIKE; 2.

SQ SEQUENCE 298 AA; 31867 MW; E0F96B8A17004317 CRC64;

Query Match

Best Local Similarity 58.8%; Score 735.5; DB 11; Length 298;

Matches 143; Conservative 35; Mismatches 57; Indels 7; Gaps 3;

QY 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSYSNVWYQAPGKLEWVAIVSYDGSNKYY 60

Db 40 QVQLQSGGGLVPGGSLKLSAASGDSFSSRYMWSVRQAPGKGLWIGINPDSSTINY 99
 QY 61 ADSVKGRTISRDNSKNTLYLQMSLRADTAATVYICARDYFD---LWGRGLTVTVSSGG 117
 Db 100 TPLSKDKFTIISRDNAKNTLYLQMSKRSIEDTALYICARASYGHSAYWGQGITVTVSSGG 159
 QY 118 GSGGGGGGGGSGSALFQ-PASVSGSGPGSITISCTGTSDDIGAVNYVSWYQYFGKAP 176
 Db 160 GSGGGGGGGGSDIELTQSPASLASVGVETVITCRASGN---IENLAWYQKQKSP 216
 QY 177 KLLIYDVNRRPSGINSRPSGSGSDTASLTISGLQAEDEADYCCSPANSGLFPGGKTV 236
 Db 217 QLLVYNKTLADGPSRPSGSGTQSLKINSLOPEDFGSYCQHFHTWTPYTFGGGTLK 276
 QY 237 TV 238
 Db 277 EI 278

RESULT 2

Q921A6 PRELIMINARY; PRT; 241 AA.
 AC Q921A6;
 DT 01-DEC-2001 (TrEMBLrel. 19, Created)
 DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
 DE Anti-CBA 79 single chain Fv fragment (Fragment).
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OX NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=98170165; PubMed=9509426;
 RA Chung J.H., Choi S.J., Kim H.J., Kim I.J., Choi I.H., Lee S.D.,
 Yi K.S., Suh P.G., Ryu S.H., Chung H.K.;
 RT "Cloning and characterization of cDNAs encoding VH and VL of a
 monoclonal anti-CEA antibody (CEA 79) cross-reactive with NCA-95 and
 generation of a single-chain Fv molecule (scFv).";
 RL Mol. Cells 7:816-819 (1997).
 DR EMBL; U88067; AAB48044.1; -.
 DR InterPro; IPR007110; IG-Like.
 DR InterPro; IPR003596; IG_V.
 DR Pfam; PF00047; IG_2.
 DR SMART; SM00406; IG; 2.
 DR PROSITE; PSS0835; IG_LIKE; 2.
 FT NON_TER 1 241
 FT NON_TER 241 241
 SQ SEQUENCE 241 AA; 26086 MW; 0276887248E9C771 CRC64;

Query Match 49.7%; Score 621; DB 11; Length 241;
 Best Local Similarity 53.7%; Pred. No. 6.6e-41;
 Matches 131; Conservative 33; Mismatches 64; Indels 16; Gaps 7;

QY 1 QVQLQSGGGLVPGGSLRLSCAASGFTFSYSSMWSVRQAPGKGLWVAIVSDGSKYY 60
 Db 1 QVQLQSGGGLVPGGSLRLSCAASGFTFSYSSMWSVRQAPGKGLWVAIVSDGSKYY 60
 QY 61 ADSVKGRTISRDNSKNTLYLQMSLRADTAATVYICARD---RYFDLWGRGLTVTVSSGG 117
 Db 61 ADDFKRFAFSLTASASTAYLIQNNLNKEDATVFCARKDLLRYFDYWGQGITVTVSSGG 120
 QY 118 GSGGGGGGGGSGSALFQ-PASVSGSGPGSITISCTGTSDDIGAVNYVSWYQYFGKAP 176
 Db 121 GSGGGGGGGGSDIELTQSPASSLASVGVETVITCK-ASQDIN--KYIAWYQKQKSP 177
 QY 177 K---LLIYDVNRRPSGINSRPSGSGSDTASLTISGLQAEDEADYCCSPANSGLFPGG 232
 Db 178 RGAHTLHIY----IQPGIPSRPSGSGSDYFSISNLEPEDIATYYCLHYDNL-HTFGG 232
 QY 233 GTKV 236
 Db 233 GTKL 236

RESULT 3

Q7TQM2 PRELIMINARY; PRT; 243 AA.
 AC Q7TQM2;
 DT 01-OCT-2003 (TrEMBLrel. 25, Created)
 DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
 DE scFv 6H8 protein (Fragment).
 GN scFv 6H8.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OX NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=Balb/C;
 RA Peter J.C., Eftekhari P., Billiald P., Wallukat G.;
 RT "scFv single chain antibody variable fragment as inverse agonist for
 the beta-2 adrenergic receptor";
 RL Submitted (JUN-2003) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AJ574851; CAE00495.1; -.
 FT NON_TER 1 243
 FT NON_TER 243 243
 SQ SEQUENCE 243 AA; 25976 MW; BEFF64D2DCFAF76 CRC64;

Query Match 48.0%; Score 600; DB 11; Length 243;
 Best Local Similarity 52.3%; Pred. No. 2.9e-39;
 Matches 126; Conservative 40; Mismatches 67; Indels 8; Gaps 7;

QY 1 QVQLQSGGGLVPGGSLRLSCAASGFTFSYSSMWSVRQAPGKGLWVAIVSDGSKYY 59
 Db 1 QVQLQSGGGLVPGGSLRLSCAASGFTFSYSSMWSVRQAPGKGLWVAIVSDGSKYY 59
 QY 60 YADVKGRTISRDNSKNTLYLQMSLRADTAATVYICAR---DRYFDLWGRGLTVTVSSGG 118
 Db 60 YDEKFNKGLITVDTSSTAYMELSSLASDSAVVYCARGGRLDWGAGTTLTVSSGG 119
 QY 119 GSGGGGGGGGSGSALFQ-PASVSGSGPGSITISCTGTSDDIGAVNYVSWYQYFGKAP 177
 Db 120 GSGGGGGGGGSDIQMTQSSSFVSLGRVITCK-ASEDI--YNNLAWYQKQKGNAPR 176
 QY 178 LLIYDVNRRPSGINSRPSGSGSDTASLTISGLQAEDEADYCCSPANSGLFPGGKTV 237
 Db 177 LLISGATSLTGVPSRPSGSGSKDYTLTSLTQEDVATYICQYV-STRTFGGGTTLE 235
 QY 238 V 238
 Db 236 I 236

RESULT 4

Q8WUK1 PRELIMINARY; PRT; 613 AA.
 AC Q8WUK1;
 DT 01-MAR-2002 (TrEMBLrel. 20, Created)
 DT 01-MAR-2002 (TrEMBLrel. 20, Last sequence update)
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
 DE Hypothetical protein.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Tonsil;
 RA Strausberg R.;
 RL Submitted (DEC-2001) to the EMBL/GenBank/DBJ databases.
 DR EMBL; BC020240; AAH20240.1; -.
 DR PIR; P0120; P0120.
 DR PIR; S15590; S15590.
 DR InterPro; IPR007110; IG-Like.
 DR InterPro; IPR003006; IG_MAC.

RESULT 7	PRELIMINARY;	PRT;	116 AA.
Q9UL93			
ID	Q9UL93		
AC	Q9UL93;		
DT	01-MAY-2000 (TREMBLrel. 13, Created)		
DT	01-MAY-2000 (TREMBLrel. 13, Last sequence update)		
DT	01-OCT-2003 (TREMBLrel. 25, Last annotation update)		
DE	Myosin-reactive immunoglobulin heavy chain variable region (Fragment).		
DE	Homo sapiens (Human).		
OS	Homo sapiens (Human).		
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
OC	Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.		
OC	NCBI TaxID=9606.		

RESULT 7	PRELIMINARY;	PRT;	116 AA.
Q9UL93			
ID	Q9UL93		
AC	Q9UL93;		
DT	01-MAY-2000 (TREMBLrel. 13, Created)		
DT	01-MAY-2000 (TREMBLrel. 13, Last sequence update)		
DT	01-OCT-2003 (TREMBLrel. 25, Last annotation update)		
DE	Myosin-reactive immunoglobulin heavy chain variable region (Fragment).		
DE	Homo sapiens (Human).		
OS	Homo sapiens (Human).		
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
OC	Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.		
OC	NCBI TaxID=9606.		

```

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
NCBI_TaxID=9606;
[1]
NRN SEQUENCE FROM N.A.
RRP MEDLINE=96071149; PubMed=7475268;
RRA Cao J., Vescio R.A., Rettig M.B., Hong C.H., Kim A., Lee J.C.,
RRA Lichtenschein A.K., Serenson J.R.;
RRA "A CD10-positive subset of malignant cells is identified in multiple
RRT myeloma using PCR with patient-specific immunoglobulin gene primers.";
RRT Leukemia 9:1948-1953(1995).
DR EMBL; S80860; RAD14339.1; -.
DR HSSP; P01772; 2FB4.
DR GO; GO:0005867; C:integral to plasma membrane; NAS.
DR GO; GO:0016489; F:immunoglobulin receptor activity; NAS.
DR GO; GO:0016066; P:cellular defense response (sensu Vertebrata); NAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF00047; IG; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PSS0835; IG_LIKE; 1.
DR NON_TER 1
FT SEQUENCE 147 AA; 15768 MW; 8489FCAAA7BC925C CRC64;
SQ
Query Match 39.5%; Score 494; DB 4; Length 147;
Best Local Similarity 67.9%; Pred. No. 3.2e-31;
Matches 106; Conservative 22; Indels 20; Gaps 3
QY 1 QVQLQSGGGLVPGGSLRLSCAASGFFESSYMSWVRQAPGKLEWAVISYDGSNKYY 60
DDB 1 QVHLFESGGGVQPGKSLRLSCAASGFFTFSTYGMWVRQAPGKGLDWALLISYDGSIOYY 60
QY 61 ADSVKGRFTISRDNSKNTYLYQMNSLRRAEDTAVYYCARD-RYF-----DLWGRGT 109
DDB 61 AGSVKGRFTISRDNSKNTLYLQMTSLRVEDTAVYYCAKDGNVFDVSGVYVAGIDYWGQGT 120
QY 110 LVTVSSGGGGGGGGGGGGGSGSALTPQASVSGSPG 145
DDB 121 LVTVSS-----ASTKGPSVFPLA-PSKSTSGG 147

```

RESULT 10	Q9UL84	PRELIMINARY;	PRT; 122 AA.
IID	Q9UL84		
AC	Q9UL84		
DT	01-MAY-2000	(T1EMBLrel. 13, Created)	
DT	01-MAY-2000	(T1EMBLrel. 13, Last sequence update)	
DT	01-OCT-2003	(T1EMBLrel. 25, Last annotation update)	
DE	Myosin-reactive immunoglobulin heavy chain variable region (Fragment).		
OS	Homo sapiens (Human).		
OC	Eukaryota;	Chordata;	Cranialia; Vertebrata; Euteleostomi;
OC	Mammalia;	Metazoa;	Chordata;
OC	Eumalia;	Primates;	Catarrhini; Homnidae; Homo.

```
AN RP SEQUENCE FROM N.A.
RX MEDLINE=98277139; PubMed=9614934;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,
SA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
  fetus.";
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
DR EMBL; AF035030; AAD56266.1; -.
DR HSP; P01772; 2FB4.
DR InterPro; IPR007110; Ig-Like.
DR InterPro; IPR003596; Ig_V.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PSS0835; IG_LIKE; 1.
FT NON TER 122 122
SQ SEQUENCE 122 AA; 13579 MW; 36054D41366545B8 CRC64;

Query Match 39.0%; Score 489.5; DB 4; Length 122;
Best Local Similarity 76.0%; Pred. No. 8.8e-31;
Matches 96; Conservative 7; Mismatches 12; Indels 7; Gaps 1;

QY 1 QVQLQSGGGGLVPGGSLRLSCAASGFTFSYSSMSGVRQAPGKLEWVAVISYDGSNKYY 60
D 1 EVQLVESGGGVQPGSLRLSCAASRFTFSYGMHWVRQAPGKLEWVAALISNDGSKNFY 60
QY 61 ADSVKGRTISRDNKNTLYLQMSLRADTAIVYCARDR-----YFDLWGRGLTVTV 113
D 61 ADSVKGRTISRDNKNTLYLQMSLRADTAIVYCARDR-----YFDLWGRGLTVTV 120
QY 114 SS 115
D 121 SS 122

RESULT 11
Q9UL71 PRELIMINARY; PRT; 121 AA.
AC Q9UL71;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region
DE (Fragment).
OS Homo sapiens (human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=98277139; PubMed=9614934;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,
SA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
  fetus.";
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
DR EMBL; AF035043; AAD56279.1; -.
DR HSP; P01772; 2FB4.
DR InterPro; IPR007110; Ig-Like.
DR InterPro; IPR003596; Ig_V.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PSS0835; IG_LIKE; 1.
FT NON TER 121 121
SQ SEQUENCE 121 AA; 13154 MW; 2F045CCFA5D50736 CRC64;

Query Match 39.0%; Score 487; DB 4; Length 121;
Best Local Similarity 76.0%; Pred. No. 8.8e-31;
Matches 92; Conservative 13; Mismatches 10; Indels 6; Gaps 1;

QY 1 QVQLQSGGGGLVPGGSLRLSCAASGFTFSYSSMSGVRQAPGKLEWVAVISYDGSNKYY 60
D 1 EVQLVESGGGVQPGSLRLSCAASRFTFSYGMHWVRQAPGKLEWVAALISNDGSKNFY 60
QY 61 ADSVKGRTISRDNKNTLYLQMSLRADTAIVYCARDR-----YFDLWGRGLTVTV 113
D 61 ADSVKGRTISRDNKNTLYLQMSLRADTAIVYCARDR-----YFDLWGRGLTVTV 120
QY 114 SS 115
D 121 SS 122

RESULT 12
Q9UL91 PRELIMINARY; PRT; 479 AA.
AC Q9UL91;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Hypothetical protein.
DE Mus musculus (mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=98277139; PubMed=9614934;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,
SA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
  fetus.";
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
DR EMBL; AF035043; AAD56279.1; -.
DR HSP; P01772; 2FB4.
DR InterPro; IPR007110; Ig-Like.
DR InterPro; IPR003596; Ig_V.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PSS0835; IG_LIKE; 1.
FT NON TER 121 121
SQ SEQUENCE 479 AA; 51603 MW; ECB2D0877748584F CRC64;

Query Match 38.8%; Score 485.5; DB 11; Length 479;
Best Local Similarity 44.9%; Pred. No. 5.3e-30;
Matches 110; Conservative 38; Mismatches 44; Indels 53; Gaps 9;

QY 1 QVQLQSGGGGLVPGGSLRLSCAASGFTFSYSSMSGVRQAPGKLEWVAVISYDGSNKYY 60
D 1 EVQLVESGGGVQPGSLRLSCAASRFTFSYGMHWVRQAPGKLEWVAALISNDGSKNFY 60
QY 61 ADSVKGRTISRDNKNTLYLQMSLRADTAIVYCARDR-----YFDLWGRGLTVTV 113
D 61 ADSVKGRTISRDNKNTLYLQMSLRADTAIVYCARDR-----YFDLWGRGLTVTV 120
QY 121 CGGGSGGGGSGSA-----LTQPASVSGSPQSITISC-----TGTSSDIGAVNVYS 166
D 121 CGGGSGGGGSGSA-----LTQPASVSGSPQSITISC-----TGTSSDIGAVNVYS 174
QY 134 -----SEPREPTIYPLTFQALSSDP---VIICLIHDFPSTWY-----VT 174
D 134 -----SEPREPTIYPLTFQALSSDP---VIICLIHDFPSTWY-----VT 174
QY 167 WYQYFGKAPKLLIYDVS--NRPGISNRFSGSKSGDTASLTISGLQAEADYICSSFA 224
D 167 WYQYFGKAPKLLIYDVS--NRPGISNRFSGSKSGDTASLTISGLQAEADYICSSFA 222
QY 175 W-----GKSGK-----DITVNFPPALA---SGGRYTMSSQLTPAVECPGEGSVKCSVQH 222
D 175 W-----GKSGK-----DITVNFPPALA---SGGRYTMSSQLTPAVECPGEGSVKCSVQH 222
QY 225 NSGSL 229
D 223 DSNPV 227

RESULT 13
Q9UL91 PRELIMINARY; PRT; 118 AA.
AC Q9UL91;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region
```

DR InterPro; IPR007110; Ig-like.

DR Inter

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

SW protein - protein search, using sw model

Run on: March 15, 2004, 07:25:43 ; Search time 17 Seconds
(without alignments)
732.045 Million cell updates/sec

Title: OS-09-620-955B-6
Perfect score: 1250
Sequence: 1 QVQLQESGGGLVQPGGSLRL.....CSSFANSGLPLFGGKTKVTVL 239

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 141681 seqs, 52070155 residues

Total number of hits satisfying chosen parameters: 141681

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : SwissProt_42.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	507.5	40.6	122	1 HV3G HUMAN	P01768 homo sapien
2	488	39.0	112	1 LV2K HUMAN	P04209 homo sapien
3	478	38.2	119	1 HV3J HUMAN	P01770 homo sapien
4	472	37.8	121	1 HV3J HUMAN	P01771 homo sapien
5	468.5	37.5	111	1 LV2B HUMAN	P01705 homo sapien
6	465.5	37.2	111	1 LV2A HUMAN	P01704 homo sapien
7	462.5	37.0	122	1 HV3H HUMAN	P01769 homo sapien
8	454.5	36.4	111	1 LV2D HUMAN	P01707 homo sapien
9	453.5	36.3	126	1 HV2K HUMAN	P01772 homo sapien
10	452.5	36.2	114	1 HV3B HUMAN	P01763 homo sapien
11	452	36.2	117	1 HV3C HUMAN	P01764 homo sapien
12	449.5	36.0	111	1 LV2H HUMAN	P01711 homo sapien
13	444	35.5	115	1 HV3D HUMAN	P01765 homo sapien
14	443	35.4	115	1 LV2F HUMAN	P01767 homo sapien
15	439.5	35.2	111	1 LV2M HUMAN	P01709 homo sapien
16	437.5	35.0	119	1 LV2G HUMAN	P01774 homo sapien
17	435.5	34.8	111	1 LV2G HUMAN	P01710 homo sapien
18	435.5	34.8	119	1 HV3N HUMAN	P01775 homo sapien
19	435.5	34.8	136	1 HV16 MOUSE	P01783 mus musculu
20	434.5	34.8	109	1 LV2E MOUSE	P01708 homo sapien
21	433.5	34.7	116	1 HV95 CARAU	P19181 carassius a
22	432.5	34.6	116	1 HV3T HUMAN	P01781 homo sapien
23	430	34.4	119	1 HV3L HUMAN	P01773 homo sapien
24	430	34.4	120	1 HV3E HUMAN	P01766 homo sapien
25	428.5	34.3	117	1 HV3G HUMAN	P01776 homo sapien
26	425	34.0	111	1 LV2J HUMAN	P01713 homo sapien
27	423.5	33.9	111	1 LV2C HUMAN	P01706 homo sapien
28	422.5	33.8	122	1 HV3A HUMAN	P01762 homo sapien
29	421.5	33.7	119	1 HV3B HUMAN	P01808 mus musculu
30	417.5	33.4	120	1 HV3U MOUSE	P01782 homo sapien
31	415.5	33.2	111	1 LV2I HUMAN	P01712 homo sapien
32	414.5	33.2	119	1 HV37 MOUSE	P01807 mus musculu
33	414.5	33.2	122	1 HV20 MOUSE	P01789 mus musculu

34	414	33.1	117	1 HV02 CANFA	P01785 canis famil
35	414	33.1	123	1 HV18 MOUSE	P01787 mus musculu
36	414	33.1	123	1 HV19 MOUSE	P01788 mus musculu
37	414	33.1	123	1 HV22 MOUSE	P01791 mus musculu
38	413	33.0	115	1 HV32 MOUSE	P01801 mus musculu
39	413	33.0	123	1 HV25 MOUSE	P01794 mus musculu
40	411	32.9	113	1 HV30 MOUSE	P01799 mus musculu
41	410.5	32.8	114	1 HV01 CANFA	P01784 canis famil
42	410	32.8	123	1 HV23 MOUSE	P01782 mus musculu
43	409	32.7	123	1 HV01 RAT	P01805 rattus norv
44	408	32.6	123	1 HV24 MOUSE	P01793 mus musculu
45	407.5	32.6	122	1 HV21 MOUSE	P01790 mus musculu

ALIGNMENTS

RESULT 1
HV3G HUMAN
ID HV3G HUMAN STANDARD; PRT; 122 AA.
AC P01768;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Ig heavy chain V-III region CAM.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN (1)_TaxID=9606;
RP SEQUENCE.
RX MEDLINE=81013859; PubMed=6774332;
RA Lehman D.W., Putnam F.W.;
RT "Amino acid sequence of the variable region of a human mu chain;
RT location of a possible JH segment.";
RL Proc. Natl. Acad. Sci. U.S.A. 77:3239-3243(1980).
CC -!- MISCELLANEOUS: THIS MU CHAIN WAS ISOLATED FROM THE PLASMA OF A
CC -!- PATIENT WITH MACROGLOBULINEMIA.
CC -!- SIMILARITY: Contains 1 immunoglobulin-like domain.
DR PIR; A02051; M3HUM.
DR HSSP; P01772; 2FB4.
DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF00047; Ig_1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
KW Immunoglobulin V region; Pyridolone carboxylic acid.
FT DOMAIN 1 112 IG-LIKE.
FT MOD RES 1 1 PYRROLIDONE CARBOXYLIC ACID.
FT NON_TER 122 122
SQ SEQUENCE 122 AA; 13668 MW; A42D0F17D252F1C3 CRC64;

Query Match 40.6%; Score 507.5; DB 1; Length 122;
Best Local Similarity 77.9%; Pred. No. 8.7e-32;
Matches 95; Conservative 13; Mismatches 7; Indels 7; Gaps 1;
QY 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSYSMSVWRQAPGKLEWVAIVSYDGSNKYY 60
DB 1 QVELVESGGGVVQPSRLSLRSCAASGFTFSYAMHWVRQPPGKLEWVAIVSYEGBBKYY 60
QY 61 ADSVKGRITISDKSKNTLYLQMSLRADTAIVYVCARD-----RYPLWGRGLTIV 113
DB 61 ABSVGRITISDKSKNTLYLQMSLRADTAIVYVCARDRLYCBYAFYWGQGLTIV 120
QY 114 SS 115
DB 121 SS 122

RESULT 2

LV2K_HUMAN
ID LV2K_HUMAN STANDARD; PRT; 112 AA.
AC P04209;
DT 20-MAR-1987 (Rel. 04, Created)
DT 20-MAR-1987 (Rel. 04, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Ig lambda chain V-II region NTG-84.
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE.
RX MEDLINE=85204383; PubMed=3922791;
RA Tansike H, Kamekuni F, Hoshi A, Shinoda T, Isobe T;
RT "Amino acid sequence of an amyloidogenic Bence Jones protein in
myeloma-associated systemic amyloidosis."
RL FEBS Lett. 185:139-141(1985).
CC -!- MISCELLANEOUS: THIS IS A BENCE-JONES PROTEIN ISOLATED FROM AN
INDIVIDUAL WITH MYELOMA-ASSOCIATED SYSTEMIC AMYLOIDOSIS.
CC -!- SIMILARITY: Contains 1 immunoglobulin-like domain.
DR PIR; A01971; L2HUNG.
DR HSSP; P01709; 2MCG.
DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF00047; IG; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 1.
KW Immunoglobulin V region, Anyloid; Bence-Jones protein.
FT DOMAIN 1 102
FT DISULFID 22 90
FT NON TER 112
FT SEQUENCE 112 AA; 11581 MW; 988PF363AE1E4F3 CRC64;
Query Match 39.0%; Score 488; DB 1; Length 112;
Best Local Similarity 84.7%; Pred. No. 2.3e-30;
Matches 94; Conservative 11; Mismatches 4; Indels 2; Gaps 1;
QY 131 QSALTQPSVSGSPQSTISCTGTSIDGAYNVSVYQYQPKAPKLLIYDVSNPSCI 190
Db 1 QSALTQPSVSGSPQSTISCTGTSIDGAYNVSVYQYQPKAPKLLIYDVSNPSCI 60
QY 191 SNRFGSKSGTASLTISGLQAEADYVCSF--ANSGLFGGKTVYL 239
Db 61 SNRFGSKSGTASLTISGLQAEADYVCSF--ANSGLFGGKTVYL 111
RESULT 3
HV3J_HUMAN
ID HV3J_HUMAN STANDARD; PRT; 119 AA.
AC P01770;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Ig heavy chain V-III region NIE.
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE.
RX MEDLINE=77070269; PubMed=826475;
RA Ponstingl H, Hilschmann N;
RT "The rule of antibody structure. The primary structure of a
monoclonal IgG1 immunoglobulin (myeloma protein NIE). III. The
chymotryptic peptides of the H-chain, alignment of the tryptic
peptides and discussion of the complete structure."
RL Hoppe-Seyler's Z. Physiol. Chem. 357:1571-1604(1976).
RN [2]
RP DISULFIDE BOND.

MEDLINE=77070267; PubMed=1002129;
RX Dreker L, Schwarz J, Reichel W, Hilschmann N;
RT "Rule of antibody structure. The primary structure of a monoclonal
IgG1 immunoglobulin (myeloma protein NIE). I: Purification and
characterization of the protein, the L- and H-chains, the
cyanogen bromide cleavage products, and the disulfide bridges."
RL Hoppe-Seyler's Z. Physiol. Chem. 357:1515-1540(1976).
CC -!- MISCELLANEOUS: THIS CHAIN WAS ISOLATED FROM AN IG G1 MYELOMA
PROTEIN.
CC -!- SIMILARITY: Contains 1 immunoglobulin-like domain.
DR PIR; A91669; GIHUNI.
DR HSSP; P01772; 2FB4.
DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF00047; IG; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 1.
KW Immunoglobulin V region; Pyrrolidone carboxylic acid.
FT DOMAIN 1 112
FT MOD RES 1 1
FT PYRROLIDONE CARBOXYLIC ACID.
FT DISULFID 22 96
FT NON TER 119
FT SEQUENCE 119 AA; 13242 MW; C9693SA6E5E165B CRC64;
Query Match 38.2%; Score 478; DB 1; Length 119;
Best Local Similarity 77.3%; Pred. No. 1.4e-29;
Matches 92; Conservative 12; Mismatches 11; Indels 4; Gaps 1;
QY 1 QVQLQSGGGLVQPGGSLRLSCAASGFTSSYMSWVRQAPGKLEWAVIYDGSNKYY 60
Db 1 QVQLVSGGGLVQPGGSLRLSCAASGFTSSYMSWVRQAPGKLEWAVIYDGSNKYY 60
QY 61 ADSVKGRTISRDNSKNTLYLQNSLRADTVYICARDR----YFDLWGRGTLTVSS 115
Db 61 ADSVNGRFTISRDNSKNTLYLQNSLRADTVYICARDTAMFFAHGQGTLTVSS 119
RESULT 4
HV3J_HUMAN
ID HV3J_HUMAN STANDARD; PRT; 121 AA.
AC P01771;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Ig heavy chain V-III region HIL.
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE.
RX MEDLINE=79124695; PubMed=420800;
RA Chiu Y.-Y. H, Lopez de Castro J.A., Poljak R.J.;
RT "Amino acid sequence of the VH region of human myeloma
cryoimmunoglobulin IgG Hil."
RL Biochemistry 18:553-560(1979).
CC -!- MISCELLANEOUS: THIS CHAIN WAS ISOLATED FROM AN IG G1 MYELOMA
PROTEIN.
CC -!- SIMILARITY: Contains 1 immunoglobulin-like domain.
DR PIR; A02054; GIHUEL.
DR HSSP; P01772; 2FB4.
DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF00047; IG; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 1.
KW Immunoglobulin V region; Pyrrolidone carboxylic acid.

CC MACROGLOBULIN.
CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
DR PIR; A02052; M3HUGA.
DR HSSP; P01772; 2FB4.
DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 1.
KW Immunoglobulin V region; Pyrollidone carboxylic acid.
FT DOMAIN 1 112 IG-LIKE
FT MOD_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.
FT NON_TER 122 122
SQ SEQUENCE 122 AA; 13166 MW; 745B56959B84100A CRC64;

Query Match 37.0%; Score 462.5; DB 1; Length 122;
Best Local Similarity 68.9%; Pred. No. 2.1e-28;
Matches 84; Conservative 19; Mismatches 12; Indels 7; Gaps 1;

QY 1 QVQLQESGGGLVQPGGSLRLSQAAGPTFSYSSMSVWVQAQKGLWVAVISYDGSNYY 60
DB 1 QVQLVSGGAGVPGKSLRLSQAAGSFSTYAMHWVQAQKGLZMLSVISYBGBZYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQNSLRARDEAVYYCARDY-----FDLWGRGTLVTV 113
DB 61 AASVKGRFTISRBBKBTWYLEWNSLRARNTAVYCARSGIALGSAVAGTDYWGZGTLVTI 120

QY 114 SS 115
DB 121 SS 122

RESULT 8
LV2D HUMAN
ID LV2D HUMAN STANDARD; PRT; 111 AA.
AC P01707;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Ig lambda chain V-II region TRO.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE.
RX MEDLINE=80114123; PubMed=118915;
RA Scholz R., Yang C., Hilechmann N.;
RT "Rule of antibody structure. Primary structure of a human monoclonal IgA1-immunoglobulin (myeloma protein Trol). VI. Amino acid sequence of the L-chain, lambda-type, subgroup II.";
RL Hoppe-Seyler's Z. Physiol. Chem. 360:1903-1918 (1979).
CC -1- MISCELLANEOUS. THIS CHAIN WAS ISOLATED FROM A MYELOMA PROTEIN.
CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
DR PIR; A01973; L2HUTR.
DR HSSP; P01709; 2MCG.
DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 1.
KW Immunoglobulin V region; Pyrollidone carboxylic acid.
FT DOMAIN 1 106 IG-LIKE
FT MOD_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.
FT DISULFID 22 90 BY SIMILARITY.
FT NON_TER 111 111
SQ SEQUENCE 111 AA; 11561 MW; 99DC457A12B9F6E1 CRC64;

Query Match 36.4%; Score 454.5; DB 1; Length 111;
Best Local Similarity 78.2%; Pred. No. 7.6e-28;
Matches 86; Conservative 13; Mismatches 10; Indels 1; Gaps 1;

QY 131 QSALTQPASVSGSPGQSITISCTSSDIGNVYVWYQYQPKAPKLLIYDVSNRPSGI 190
DB 1 QSALTQPRSVSGSPGQVTSCTTSDDVGAYNSVWYQYQPKAPKLMIFDVKRPSGV 60

QY 191 SNRPSGSGDTSALTISGLQAEADYVYCSSPANS-GPLFGGQTKVTVL 239
DB 61 PDLRSGSKSGDTSALTISGLRADDEADYVYCSVAGRYSVIFGGTKLTVL 110

RESULT 9
HV3K HUMAN
ID HV3K HUMAN STANDARD; PRT; 126 AA.
AC P01772;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Ig heavy chain V-III region KOL.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE, AND DISULFIDE BONDS.
RX MEDLINE=83289131; PubMed=6884994;
RA Schmidt W.E. Jung H.-D. Palm W., Hilechmann N.;
RT "Three-dimensional structure determination of antibodies. Primary structure of crystallized monoclonal immunoglobulin IgG1 KOL, I.";
RL Hoppe-Seyler's Z. Physiol. Chem. 364:713-747 (1983).
RN [2]
RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS).
RX MEDLINE=81072295; PubMed=7441755;
RA Marquart M., Deisenhofer J., Huber R., Palm W.;
RT "Crystallographic refinement and atomic models of the intact immunoglobulin molecule KOL and its antigen-binding fragment at 3.0 A and 1.0-A resolution.";
RL J. Mol. Biol. 141:369-391 (1980).
CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
DR PIR; A02055; GIHUKL.
DR PDB; 2FB4; 12-JUL-89.
DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 1.
KW Immunoglobulin V region; 3D-structure; Pyrollidone carboxylic acid.
FT DOMAIN 1 112 IG-LIKE
FT MOD_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.
FT DISULFID 22 96
FT DISULFID 105 110
FT STRAND 3 7
FT STRAND 11 12
FT TURN 14 15
FT STRAND 18 25
FT STRAND 29 31
FT HELIX 29 31
FT STRAND 34 39
FT TURN 41 42
FT STRAND 45 51
FT TURN 53 54
FT STRAND 58 60
FT STRAND 62 64
FT HELIX 62 65
FT STRAND 65 65
FT TURN 66 67
FT STRAND 68 73
FT TURN 74 77

DR	HSP; P01772; 2FB4.
DR	GO: GO:0005576; C:extracellular; NAS.
DR	GO: GO:0003823; F:antigen binding; NAS.
DR	GO: GO:0006955; P:immune response; NAS.
DR	InterPro: IPR007110; IG-like.
DR	InterPro: IPR003596; IG_v.
DR	Pfam: PF00047; IG.1.
DR	SMART; SM00406; IGV; 1.
DR	PROSITE; PS00835; IG_LIKE; 1.
DR	Immunoglobulin V region.
FT	DOMAIN 1 108 IG-LIKE:
FT	NON_TER 115 115
SEQ	SEQUENCE 115 AA; 12356 MW; 4DCC67D179F62326 CRC64;
Query Match 35.5%; Score 444; DB 1; Length 115;	
Best Local Similarity 73.9%; Pred. No. 4.8e-27;	
Matches 88; Conservative 10; Mismatches 13; Indels 8; Gaps 2;	
QY	1 QVQLQESGGGLVQPGGSLRLCAASGFTFSYMSWVRQAPGKLEWAVISVDGSKYY 60
DB	1 EYQLLESGGGLVQPGGSLRLCAASGFTFSYMSWVRQAPGKGLZVWGAIZGLSVSZSY 60
QY	61 ADSVKGRTISRDNKNTLYLQMSLRAEDTAVYYCARDR---YFDLWGRGTLVTYSS 115
DB	61 ABSVKGRTISRDNKNT---VMSLRAEDTAVYYCAKGVSAVYFYWVGZGTLVTYSS 115
RESULT 14	
ID	HV3F HUMAN STANDARD; PRT; 115 AA.
ID	P01767;
DT	21-JUL-1986 (Rel. 01, Created)
DT	21-JUL-1986 (Rel. 01, Last sequence update)
DT	10-OCT-2003 (Rel. 42, Last annotation update)
DE	IG heavy chain V-III region SUBT.
OS	Homo sapiens (Human).
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
NCBI	TaxID=9606;
RP	[1]
RP	SEQUENCE
EX	MEDLINE=78137069; PubMed=416441;
RT	Torano A., Putnam F.W.;
RT	"Complete amino acid sequence of the alpha 2 heavy chain of a human
RT	IGA2 immunoglobulin of the A2m (2) allotype.";
RL	Proc. Natl. Acad. Sci. U.S.A. 75:966-969(1978).
CC	-1- MISCELLANEOUS; THE SEQUENCE OF THE ALPHA-2, A2M(2) ALLOTYPE, C
CC	REGION OF THIS MYELOMA PROTEIN IS ALSO GIVEN.
CC	-1- SIMILARITY; Contains 1 immunoglobulin-like domain.
CC	PIR; A02050; A2HCBU.
DR	HSP; P01789; 1MCP.
DR	GO: GO:0005576; C:extracellular; NAS.
DR	GO: GO:0003823; F:antigen binding; NAS.
DR	GO: GO:0006955; P:immune response; NAS.
DR	InterPro: IPR007110; IG-like.
DR	InterPro: IPR003596; IG_v.
DR	Pfam: PF00047; IG.1.
DR	SMART; SM00406; IGV; 1.
DR	PROSITE; PS00835; IG_LIKE; 1.
DR	Immunoglobulin V region.
FT	DOMAIN 1 111 IG-LIKE.
FT	NON_TER 115 115
SEQ	SEQUENCE 115 AA; 12379 MW; 208876A7DF52DCF4 CRC64;
Query Match 35.4%; Score 443; DB 1; Length 115;	
Best Local Similarity 75.0%; Pred. No. 5.8e-27;	
Matches 87; Conservative 13; Mismatches 14; Indels 2; Gaps 2;	
QY	1 QVQLQESGGGLVQPGGSLRLCAASGFTFSYMSWVRQAPGKLEWAVISVDGSKYY 60
DB	1 EYQLVETGGGLVQPGGSLRLCAASGFTFSVSHSNWVRQAPGKALZKVAI-YRGGTTY 59
QY	61 ADSVKGRTISRDNKNTLYLQMSLRAEDTAVYYCARD-RYFDLWGRGTLVTYSS 115

